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Abstract 
The thesis addresses questions of diagnosis and prognosis in connective tissue disease 
associated hypertension, as addressed in analyses of clinical data from our patients over the last 
15 years.  
Chapter 1 explores use of pulmonary function tests to improve the detection of patients at risk of 
pulmonary hypertension. A novel formula is derived and validated.  
Chapter 2 evaluates whether the formula described in the previous chapter can be combined 
with echocardiography and other measures in order to further improve the selection of patients 
for right heart catheterisation.  
In chapter 3 we turn to the prognostic value of ‘borderline pulmonary hypertension’, exploring 
indicators of future progression to pulmonary hypertension with important implications for 
patient care. 
In chapter 4 we scrutinise our data on body size and inspected the relationship between obesity 
and pulmonary hypertension, finding intriguing associations which have not been reported 
before in this population. 
Chapter 5 addresses the very rare diagnosis of lupus associated pulmonary hypertension and 
compares this small group of patients to scleroderma patients with pulmonary hypertension in 
order to consider whether their response to treatment and prognosis are distinct. 
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For chapter 6 we review the relationship between cross-sectional imaging and pulmonary 
haemodynamics, and specifically address CT findings suggestive of the rare pulmonary veno-
occlusive disease. 
In chapter 7 we turn our attention to the unfortunate group of patients with systemic sclerosis 
who develop interstitial lung disease and pulmonary hypertension. We compare their survival to 
those patients who have pulmonary hypertension without interstitial lung disease and find that 
lower Kco is most closely associated with poor outcome. 
In chapter 8 we review our cohort of patients with systemic sclerosis and pulmonary 
hypertension and consider whether pulmonary function tests can be combined with pulmonary 
haemodynamic measures to improve prognostication. 
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Preface 
Systemic sclerosis (SSc) is a rare, deadly disease which can cause catastrophic complications, 
especially interstitial lung disease
1
 and pulmonary hypertension.
2
 This research has been 
performed since January 2010 as part of my academic and clinical roles within the scleroderma 
and pulmonary hypertension services at the Royal Free Hospital, initially as a clinical research 
fellow and then as a consultant physician. 
I set out to analyse our large experience over the last 15 years in order to improve clinical 
management of these rare and very serious conditions. The sequence of the chapters follows a 
typical patient’s path, with chapters 1-4 focusing on diagnosis of pulmonary hypertension, 
chapters 5-6 with clinical course of the disease and unusual presentations, and chapters 7-8 with 
natural history and prognosis. 
In chapter 1 I explore whether pulmonary function tests can be used to improve the detection of 
patients at risk of pulmonary hypertension. In this chapter I generated a formula to predict the 
mean pulmonary artery pressure based on a combination of oxygen saturation and measurement 
of diffusion of carbon monoxide. This formula was then generated and validated in separate 
patient groups within our cohort. 
Then in chapter 2 I consider whether the formula described in the previous chapter can be 
combined with echocardiography and other measures in order to further improve the selection 
of patients for right heart catheterisation.  
In chapter 3 we explore the significance of the pulmonary haemodynamic measurements in 
patients in whom right heart catheterisation does not find pulmonary hypertension. Can we 
identify indicators of future progression to pulmonary hypertension? Are there important 
indicators associated with future progression within the haemodynamic data collected? We 
found that there are, and these findings may have important implications for patient care. 
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In chapter 4 we scrutinise our data on body size and inspected the relationship between obesity 
and pulmonary hypertension. We found intriguing associations which have not been reported 
before in this population. 
In chapter 5 we address the very rare diagnosis of lupus associated pulmonary hypertension and 
compare this small group of patients to scleroderma patients with pulmonary hypertension in 
order to consider whether their response to treatment and prognosis are distinct. 
For chapter 6 we reviewed CT scans performed near the time of the patient’s right heart catheter 
in order to test the relationship between cross-sectional image findings and pulmonary 
haemodynamics. We explore here the significance of CT findings suggestive of the rare 
pulmonary veno-occlusive disease. We find less pulmonary veno-occlusive disease in this 
patient group than has recently been described. 
In chapter 7 we turn our attention to the unfortunate group of patients with systemic sclerosis 
who develop interstitial lung disease and pulmonary hypertension. We compare their survival to 
those patients who have pulmonary hypertension without interstitial lung disease. We find that 
Kco is an important prognostic indicator in this cohort. 
In chapter 8 we review our cohort of patients with systemic sclerosis and pulmonary 
hypertension and consider whether pulmonary function tests can be combined with pulmonary 
haemodynamic measures to improve prognostication. We find that they can. 
I have learnt a huge amount in performing these analyses, and I hope I have managed to shed a 
little light here and there on areas of these rare diseases. 
I would like to acknowledge the tremendous support that I have received while doing this work. 
It would not have been possible without the continuing personal and professional support and 
encouragement of Professor Chris Denton and Dr Gerry Coghlan. I am very grateful to them 
that they offered me a Consultant post at the Royal Free and took it on trust that I would see this 
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M.D. through to its completion, (although of course the research continues in several different 
directions). 
I would like to thank all the staff of the Rheumatology and Pulmonary Hypertension 
departments at the Royal Free. I feel deeply indebted to Professor Athol Wells at the Royal 
Brompton Hospital, who besides being a crucial collaborator on several of the studies performed 
here and a world-respected colleague, helped me personally by sharing his passion for medical 
statistics and clinical research and introducing me to STATA. 
I would like to thank the Raynaud’s and Scleroderma Association for funding some of my 
ongoing research. 
Finally, I owe a debt of gratitude to my wife, Leah, my children and the Almighty. 
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Introduction 
Systemic sclerosis is a multisystem disorder of unknown aetiology which may have several 
presentations. The current classification was introduced in 1988
3
 and expanded in 2001.
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Classification is based on the amount of skin involvement. If skin involvement is limited to face 
and distally to elbows and knees, the disease is classified as limited cutaneous systemic sclerosis 
(LcSSc). If skin involvement is more extensive it is classified as diffuse cutaneous systemic 
sclerosis (DcSSc). Rarely, a diagnosis can be made in the absence of skin involvement 
(scleroderma sine scleroderma). The previously described Calcifications, Raynaud’s 
phenomenon, esophageal hypomotility, sclerodactyly, and telangiectasia (CREST) syndrome is 
no longer felt to be a useful diagnostic category, as patients with either LcSSc or DcSSc may 
have these clinical features.
5
 
LcSSc is characterised by Raynaud’s phenomenon, which usually precedes other symptoms by 
several years. The Raynaud’s phenomenon may be severe and may cause digital ulcers or 
necrosis. It is associated with anti-nuclear antibodies which stain in an anti-centromere pattern 
in about 38% of patients.
6
 Capillaroscopy usually reveals tortuous, dilated capillaries, which 
may help to distinguish these patients from the much more common primary Raynaud’s 
phenomenon. Skin thickening usually begins on the fingers (sclerodactyly) and around the 
mouth and nose. 
DcSSc, on the other hand, has a more sudden and progressive onset. There is much more 
extensive disease and more rapid progression. It is associated with anti-topoisomerase-1 (also 
known as anti-Scleroderma-70) in about a third.6 Most internal organ complications are more 
common in patients with diffuse disease, and these tend to occur in the first three years. After 
that, major organ complications are less likely and skin often improves. 
Interstitial lung disease occurs in about 38% of DcSSc and 16% of LcSSC within 5 years after 
the first non-Raynaud’s symptoms of Scleroderma.7 Two randomised controlled trials suggest 
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immunosuppression with cyclophosphamide may have a role in treatment of scleroderma 
associated interstitial lung disease, although the benefits were limited.
8
 
Renal crisis occurs in about 15% of DcSSc, and 5% of LcSSc, and is characterised by an abrupt 
onset of renal failure and severe hypertension. About 25% of patients require dialysis.
9
 
Patients frequently suffer with gastrointestinal manifestations. Upper GI involvement leads to 
dysphagia and reflux and, in severe cases, early satiety and post-prandial vomiting. Bacterial 
overgrowth frequently leads to chronic diarrhoea. Colonic dysmotility may cause constipation. 
And the anal sphincter is often affected leading to faecal incontinence.
10
 
There is some evidence that annual internal organ assessments with lung function tests, 
echocardiography and renal function tests are associated with increased survival.7 
Pulmonary hypertension is seen at least 8% of systemic sclerosis patients, whether limited or 
diffuse.2 It may be difficult to recognise in patients with systemic sclerosis because dyspnoea 
may be caused by many other causes, including anaemia, deconditioning, interstitial lung 
disease, left ventricular diastolic dysfunction among others.
11
 
Currently, the diagnosis of pulmonary hypertension can only be established by cardiac 
catheterisation. This test is expensive, invasive and associated with some risk, there is a 
concerted international effort to improve on patient selection for the test, in an attempt to 
balance the need for early diagnosis of pulmonary hypertension with minimising the number of 
unnecessary tests. 
Although there are now three classes of licensed therapies, survival in systemic sclerosis 
associated pulmonary hypertension remains poor, with a median 3 year survival of only 52% in 
a recent systematic review.
12
 
In the following chapters we explore issues relating to pulmonary hypertension in systemic 
sclerosis, with an emphasis on interrogating our retrospective data to find clues to improve 
diagnosis and to aid in prognostication in this rare but life shortening disease.  
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Chapter 1. Improving the detection of 
pulmonary hypertension in systemic 
sclerosis using pulmonary function 
tests 
E-presentation at Annual Scientific Meeting of the European Respiratory Society, Barcelona, 
September 2010 
Schreiber BE, Valerio CJ, Keir GJ, Handler C, Wells AU, Denton CP, Coghlan JG. Improving 
the detection of pulmonary hypertension in systemic sclerosis using pulmonary function tests. 
Arthritis Rheum. 2011 Nov;63(11):3531-9. 
Winner of Hench Award, ACR 2013 
Abstract 
Objectives 
To construct a readily applicable formula for selecting patients with systemic sclerosis for right 
heart catheterisation based on pulmonary function tests. 
Methods 
The diagnostic value of pulmonary function test variables
 
was quantified in 386 patients with 
systemic sclerosis against right heart catheter data. 
Results 
We derived the following formula in 257 patients: 
Predicted mean pulmonary artery pressure = 136  –  SpO2  –  0.25 x DLCO% predicted 
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We validated the formula in 129 other patients. The area under the curve is 0.74 (95% CI 
0.65,0.83). Using a predicted threshold of 25 mmHg, sensitivity is 93.8% (95% CI 86.2,98) and 
specificity is 25% (95% CI 13.6,39.6). 
When used as a screening procedure in a typical scleroderma population it is projected that 
patients with predicted mean pulmonary artery pressure below 25 mmHg are unlikely to have 
pulmonary hypertension (prevalence 4.4%), those with predicted pulmonary artery pressures 
between 25 to 35 mmHg are at average risk (prevalence of 11%) and those with formula 
predicted mean pulmonary artery pressures above 35 mmHg are likely to have pulmonary 
hypertension (prevalence of 69%), justifying right heart catheterization. 
In patients with equivocal echocardiography a high formula predicted pressure is strongly 
associated with the presence of pulmonary hypertension.  
Conclusions 
We have derived and validated an easily applicable pulmonary function formula for patients 
with systemic sclerosis which identifies sub-groups with low, average and high prevalence of 
pulmonary hypertension. It provides information which is complementary to echocardiography 
and which should improve selection of patients for right heart catheterization. 
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Introduction 
Pulmonary hypertension occurs in up to 12% of patients with systemic sclerosis (SSc).
13
 Early 
identification and treatment of pulmonary hypertension (PH) is important, and may improve 
survival.7 Although right heart catheterisation (RHC) remains the gold standard test for 
diagnosing PH, it is invasive and is not ideal as a screening test. Pulmonary function tests (PFT) 
are recommended as part of annual screening tests in SSc. However, it is not clear which 
patients require RHC based on PFT findings. 
In this study we explore the utility of pulmonary function tests and oxygen saturation in 
detecting PH in a large cohort of patients with SSc who have undergone RHC. We sought to 
develop a formula based on oxygen saturation and PFTs which would be of help to select which 
patients require RHC. In order to derive and validate the formula we split our sample into 
separate derivation and validation cohorts. We compared our formula to other pulmonary 
function test based formulae. We then assessed the diagnostic use of our formula in patients 
with contemporary echocardiography to examine whether pulmonary function tests provide 
information which is complementary to echocardiography and whether it may help decision 
making in patients with equivocal echocardiographic findings. Finally, we tested the formula in 
a cohort of patients with other connective tissue diseases associated with pulmonary 
hypertension. The information is derived from a large ‘real life’ clinical cohort and results 
should be readily applicable to scleroderma cohorts elsewhere. 
Patients and Methods  
Patients 
This study utilized the large cohort of SSc cases that underwent a diagnostic RHC study in our 
centre. Of the 838 patients with SSc 50 had additional features of overlap connective tissue 
disease (SLE in 23 patients, myositis in 15 patients, rheumatoid arthritis in 9 patients, Sjogrens 
syndrome in 7 patients, vasculitis in 1 patient and antiphospholipid syndrome in 1 patient). 
Patients with SSc overlap syndromes were included. Patients were classified as limited 
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cutaneous or diffuse cutaneous subset according to the criteria described by LeRoy et al.3 Of 
these 838 patients, 386 patients had complete PFTs (FVC % predicted, DLCO% predicted and 
KCO% predicted) within six months of the RHC and SpO2 at the time of RHC and were included 
in the study. Patients with incomplete PFT data were excluded. There were no other exclusion 
criteria. Patients in the study cohort (n=386) were a little younger and more frequently male 
than excluded patients (n=452) but mean pulmonary artery pressures and mean oxygen 
saturation were similar. Excluded patients did not differ significantly from the study cohort in 
RHC data or oxygen saturation. 
Investigations were performed as part of routine clinical care. Catheterisation was performed in 
scleroderma patients with echocardiographic tricuspid jet velocity >3.2 metres/second, in 
patients with tricuspid jet velocity between 2.8 and 3.2 if there was any clinical suspicion of 
pulmonary hypertension and in patients with tricuspid jet velocity below 2.8 if there was a 
strong clinical suspicion or unexplained progression of exertional dyspnoea.  
Patients were divided randomly in a 2:1 ratio into derivation and validation cohorts by 
generating a random number between 0 and 1 for each patient, and allocating those with a 
number less than two thirds to the derivation cohort and the others to the validation cohort. 
We then applied the formula to a separate population of patients with CTDs other than SSc who 
were referred to the Royal Free Pulmonary Hypertension service (London, UK) and underwent 
their first RHC between September 1996 and May 2010. There were 147 patients with a variety 
of CTDs in our database (59 SLE, 22 RA, 42 UCTD, 9 MCTD, 12 DM, 15 PM, 12 Sjogrens). 
Contemporary PFT data, within six months of the RHC, was available in 52 of these patients 
(SLE 17, UCTD 15, RA 7, DM 4, PM 3, MCTD 3, Sjogren’s syndrome 2, HSP 1) and they 
were included in the validation analysis. 
Clinical Data 
Pulse oximetry measurements were taken at the time of the RHC. Data on smoking status 
weight and height were collected at the time of PFTs. PFTs were performed at the Royal Free 
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Hospital or the Royal Brompton Hospital. We defined PH as a resting mPAP of ≥ 25 mmHg.14 
Echocardiography was performed in the referring hospital or at the Royal Free Hospital. 
Pulmonary artery pressures were estimated from tricuspid jet maximal velocity using the 
simplified Bernoulli equation. 
Data Analysis 
Analyses were performed using STATA
®
 software (STATA version 10.0 for Windows, Texas, 
USA). Data were expressed
 
as means (SD) or medians (range), depending on distribution.
 
Group 
comparisons were made using Student's t test or chi-squared as appropriate.
  
A P value of less 
than 0.05 was considered significant. 
Univariable linear regression was performed to identify variables of interest for the 
multivariable linear regression. Variables with statistical significance (p<0.05) were included in 
the multivariable linear regression. We found that DLCO % predicted and SpO2 explained 13-
14% of the variability in mPAP (p<0.0005, R
2 
 was 13.1 and 13.7 respectively), KCO % 
predicted provided similar information to DLCO % predicted and other variables were less 
informative [Table 1]. We therefore proceeded to multivariable linear regression using DLCO % 
predicted and SpO2. 
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Table 1. Univariable regression against mean pulmonary artery pressures was performed in the 386 patients 
in the study to identify variables of interest. 
Variable P value R
2
 
Gender 0.499 0.3% 
Age 0.377 0.6% 
DLCO % predicted <0.0005 13.1% 
SpO2 <0.0005 13.7% 
FVC % predicted 0.023 1.4% 
Scleroderma-70 0.002 2.9% 
Centromere 0.006 2.3% 
Smoker (0=never, 0.5=previous, 1=present) 0.138 0.7% 
Weight 0.001 3.5% 
Body Mass Index 0.069 1.0% 
 
Using multiple variable linear regression in the derivation cohort, we explored the relationship 
between SpO2, PFTs, clinical subtype, autoimmune serology and the mean pulmonary artery 
pressure (mPAP) on RHC and derived a formula for predicted mPAP. 
We used split sample derivation and validation. We performed subgroup analysis by clinical 
subtypes (limited or diffuse), serological subtype (anti-centromere or anti-topoisomerase I 
(scleroderma-70) antibody), smoking status and lung function. We compared the performance 
of our formula to other existing formulae and to echocardiography. Finally, we tested the 
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formula in a population of patients with CTDs other than SSc who underwent RHC at the same 
institution over the same timeframe. 
Results 
Study Population 
Within the study sample of 386 patients, 243 patients (63.0%) had pulmonary hypertension. The 
mean number of days between PFTs and RHC was 54.3 (SD 50.8). Comparing patients with PH 
(n=243, mean mPAP 37.7 mm Hg) to those without (n=143, mean mPAP 19.2 mm Hg), age and 
gender were similar. Oxygen saturation was lower in patients with PH (mean 94.3%) than in 
those without PH (mean 96.3%, p<0.005). Diffusion of carbon monoxide (DLCO) % predicted 
was also lower in those with PH (mean 38.6%) than in those without (mean 50.0%, p<0.005). 
The subtype of scleroderma (limited or diffuse) was not associated with presence of PH 
(p=0.75). Patients with PH were more frequently anti-centromere antibody positive (n=206, 
38.3%) than those without (n=131, 28.2%) although statistical significance was not reached 
(p=0.057 for comparison). Patients with PH were less likely to carry the anti-scleroderma-70 
antibody (16.2%) than those without (28.5%, p=0.007). 
Patients with pulmonary hypertension (n=243) were classified as respiratory disease associated 
(Group 3 in the Dana Point classification of pulmonary hypertension) in 113 patients (FVC 
predicted <80%), left heart disease associated (defined by pulmonary capillary wedge pressure 
above 15 mmHg at right heart catheterization) in 33 patients (Group 2) and pulmonary arterial 
hypertension in 114 patients (Group 1). 
The derivation (n=257) and validation (n=129) cohorts were well matched with respect to age, 
gender, prevalence and severity of PH, clinical subtypes, PFT data, autoimmune serology and 
smoking status. 
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Identifying Variables of Interest 
Univariate linear regression was performed to identify variables of interest for the multivariable 
linear regression. We found that DLCO % predicted and SpO2 explained 13-14% of the 
variability in mPAP (p<0.0005, R
2 
 was 13.1 and 13.7 respectively), KCO % predicted provided 
similar information to DLCO % predicted and other variables were less informative. We 
therefore proceeded to multivariable linear regression using DLCO % predicted and SpO2. 
Derivation of a Formula Based On DLCO % predicted and SpO2 
DLCO % predicted and SpO2 were both significantly associated with mPAP (p<0.0005). 
Regression using DLCO % predicted and oxygen saturation gave R
2
 of 23.1%. This gave a 
formula of predicted mPAP = 130.88 – 0.95 x SpO2 – 0.24 x DLCO% predicted. This can be 
simplified to: 
Predicted mPAP = 136 – SpO2 – 0.25 x DLCO % predicted 
No colinearity was found between SpO2 and DLCO % predicted. We tested whether the time 
interval between RHC and PFT influenced the result by analyzing separately those patients in 
the derivation cohort who had PFTs within 60 days (n=154) and those whose PFTs were done 
more than 60 days before or after their RHC (n=103). The area under the curve was 0.75 in both 
cases (p=0.97), suggesting that the relationship between PFTs and presence of pulmonary 
hypertension is similar in the two groups. 
Influence of Low Forced Vital Capacity on Multivariable Model 
FVC % predicted did not associate with pulmonary artery pressures in multivariable linear 
regression (p=0.37). However, on separate analyses in patients with low or preserved FVC, a 
clear difference was seen between those with FVC<60% predicted (n=54, R
2
=13.0%) and those 
with FVC≥60% predicted (n=203, R2=35.0%). 
Autoantibody Status 
Compared to the simple model described above (DLCO % predicted and Oxygen Category) 
addition of centromere antibody status (1 if positive, 0 if negative) was associated with mPAP 
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(p=0.006) and improved model fit (R
2
 increases from 23.1 to 26.4). Scleroderma-70 antibody 
was more tightly associated (p<0.0005, R
2
 increases from 23.1 to 27.1) and when both 
scleroderma-70 and centromere were added, scleroderma-70 remained strongly significant 
(p<0.0005) but centromere became non-significant (p=0.43). 
Testing of the Formula in the Validation Cohort 
Applying this simplified formula in the validation cohort (n=129) gave an area under the curve 
of 0.75 (95% CI 0.67,0.84), and an R
2
 value of 22.3%. A scatterplot is shown in Figure 1. 
Figure 1. Scatterplot of predicted and measured mean pulmonary artery pressure in the validation cohort  
  
Using a predicted threshold of 25 mmHg to diagnose pulmonary hypertension, the sensitivity 
was 90.1% (95% CI 82,96), specificity 29.2% (95% CI 17,44), positive likelihood ratio 1.3 
(95% CI 1.05,1.55) and negative likelihood ratio 0.3 (95% CI 0.2,0.7). A Bland-Altman plot 
showed a mean difference between predicted and measured mPAP of 1.1 (95% limits of 
agreement -20.4,22.6). It can be seen that there is better agreement in lower pulmonary 
pulmonary artery pressures and a trend to underestimate very high pressures [Figure 2]. 
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Figure 2. bland-altman plot showing level of agreement between formula predicted and actual right heart 
catheterisation 
 
Using a predicted threshold of 30mmHg to diagnose pulmonary hypertension, the sensitivity 
was 59.3% (95% CI 47.8,70.1) and the specificity was 70.8% (95% CI 55.9,83.0). Using a 
predicted threshold of 35 mmHg to diagnose pulmonary hypertension, the sensitivity fell to 
25.9% (95% CI 16.8,36.9) but the specificity rose to 97.9% (95% CI 88.9,99.9). 
We can therefore estimate the prevalence of pulmonary hypertension in a typical scleroderma 
cohort with a prevalence of 12%.13 Patients with predicted mPAP below 25 mmHg have a low 
prevalence of pulmonary hypertension of 4.41% (95% CI 2.1,9.3). Those with intermediate 
predicted mPAP between 25 and 35 mmHg have an average risk of PH of 11.3% (95% CI 
9.0,14.1). Those with a formula predicted mPAP above 35 mmHg have a high prevalence of PH 
of 62.9% (95% CI 19.1,92.4). 
Thus, a predicted mPAP below 25 mmHg indicates a group with a low prevalence of PH. A 
predicted mPAP of 25-35 mmHg indicates a group with average incidence, and those patients 
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with formula predicted mPAP above 35 mmHg have a high prevalence of pulmonary 
hypertension. 
Subgroup Comparisons 
We explored the relationship between predicted and measured mPAP in subgroups within our 
combined study cohort. We examined the effect of disease subtype, autoantibody, restrictive 
lung disease, raised pulmonary capillary wedge pressures and smoking on the relationship 
between predicted and measured mPAP [Table 2]. 
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Table 2. Results of linear regression to predict pulmonary artery pressures based on oxygen saturation and 
DLCO in subgroups of patients with systemic sclerosis 
 Number 
of patients 
Area under 
the curve 
(95% CI) 
Sensitivity Specificity R
2
 
All patients 386 0.75 
(0.70,0.80) 
90.9% 
(86.6,94.2) 
35.0% 
(27.2,43.4) 
22.8% 
LcSSc 284 0.75 
(0.70.0.81) 
91.1% 
(86.0,94.8) 
34.6% 
(25.6,44.6) 
26.6% 
DcSSc 91 0.74 
(0.64,0.85) 
89.3% 
(78.1,96.0) 
37.1% 
(21.5,55.1) 
10.0% 
Anti-Centromere 
positive 
116 0.87 
(0.80,0.94) 
89.9% 
(81.0,95.5) 
62.2% 
(44.8,77.5) 
41.8% 
Scleroderma-70 
positive 
69 0.75 
(0.64,0.87) 
96.9% 
(83.8,99.9) 
13.5% 
(4.54,28.8) 
23.0% 
FVC<80% 167 0.69 
(0.61,0.77) 
95.6% 
(90.0,98.5) 
13.0% 
(5.4,24.9) 
14.0% 
FVC>80% 219 0.79 
(0.73,0.85) 
86.9% 
(79.9,92.2) 
48.3% 
(37.6,59.2) 
29.6% 
Raised 
Pulmonary 
Capillary Wedge 
Pressure 
34 0.60 
(0.37,0.82) 
76.9% 
(56.4,91.0) 
50.0% 
(15.7,84.3) 
17.8% 
Smokers (past 
and present) 
134 0.73 
(0.63,0.82) 
94.3% 
(87.2,98.1) 
34.8% 
(21.4,50.2) 
10.1% 
Non-smokers 181 0.75 
(0.68,0.82) 
89.9% 
(81.7,95.3) 
35.9% 
(26.1,46.5) 
19.2% 
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It is notable that the formula performs well in patients with anticentromere antibodies, with an 
area under the curve of 0.87 (0.80,0.97). This may be because patients with anticentromere 
antibodies have less restrictive lung disease than other patients (mean FVC % predicted 100.2% 
in patients with anticentromere antibodies and 77.8% in patients without, p<0.0005 for the 
difference). Hypoxia in patients with anticentromere antibodies is therefore likely to directly 
reflect pulmonary vasculopathy. The prevalence of pulmonary hypertension was not 
significantly higher in patients with anticentromere antibodies than in those without (68.1% and 
60.7% respectively, p=0.17 for the comparison). 
Of the total 386 patients in our study, 34 had raised pulmonary capillary wedge pressure 
(>15mmHg). The area under the curve in these patients (0.60, 95% CI 0.37-0.82) was not 
different to the area under the curve for patients with normal wedge pressure (0.77, 95% CI 
0.72-0.82, p=0.15 for the comparison). The sensitivity and specificity of the formula for 
predicting pulmonary hypertension in the validation cohort are not significantly affected by the 
removal of the patients with high wedge pressures (Sensitivity 93.0%, specificity 37.1% with 
these patients excluded, compared to sensitivity 91.4% and specificity 37.9% overall).  
243 had pulmonary hypertension at right heart catheter (mPAP≥25mmHg). We analysed the 
performance of the formula in identifying pulmonary arterial hypertension (defined as 
mPAP≥25mmHg, pulmonary capillary wedge pressure ≤15mmHg, and FVC >80% predicted to 
exclude major interstitial lung disease). 115 patients of the 386 patients met this definition. In 
these patients, correlation between predicted and actual mean pulmonary artery pressures was 
0.45 compared to 0.35 in the 243 patients with pulmonary hypertension.  
In order to clarify the effect of interstitial lung disease on the formula, we analysed separately 
the performance of the formula in a subgroup of patients in the validation cohort with no 
significant restrictive lung disease (FVC > 80% predicted) and no interstitial lung disease on CT 
chest. The overall performance of the formula was not significantly improved in this group 
without significant lung disease (AUC 0.79, 95% CI 0.69-0.88) compared to patients in the rest 
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of the validation cohort (AUC 0.74, 95% CI 0.67-0.82, p=0.49 for the comparison). The 
incidence of pulmonary hypertension was not different in these two groups (66.0% in patients 
without lung disease, 61.2% in those with lung disease, p=0.45 for the comparison).  
Comparison to Echocardiography 
Echocardiography within three months of the RHC was available in 96 patients in our study (63 
in derivation and 33 in the validation cohorts). In these patients, the AUC for echo derived TV 
gradient (AUC 0.73, 95% CI 0.63,0.83) was similar to that for the new formula in the same 
patients (AUC 0.75, 95% CI 0.64,0.86, p=0.78 for the comparison). There is similarly no 
difference between the AUC of echocardiography and the formula in the 63 patients in the 
derivation cohort alone (p=0.93 for the comparison). Using an echocardiographic cut-off of 
tricuspid regurgitant velocity > 2.8 m/s, sensitivity was 73.3% (95% CI 60.3, 83.9) and 
specificity 44.4% (95% CI 27.9,61.9). With the higher recommended cut off of TR jet velocity 
> 3.4 m/s, sensitivity was 33.3% (95% CI 21.7,46.7) and specificity was 97.2% (95% CI 
85.9,99.9). 
Logistic regression shows that after adjustment for echocardiography patients with formula 
predicted mPAP of 25mmHg or more have an odds ratio of 10.3 (95% CI 1.5-54.1, p=0.006) for 
the presence of pulmonary hypertension in the validation cohort (n=63), and an odds ratio of 9.2 
(95% CI 2.6-32.5, p=0.001) for pulmonary hypertension in both cohorts combined (n=96). 
In fact, logistic regression in the 25 patients who had echo RVSP in the range considered 
equivocal in current guidelines (RVSP between 37 and 50) showed that in these patients a 
formula predicted mPAP of 25mmHg or more is associated with an odds ratio of 12.8 (95% CI 
1.0-157.1, p=0.047) for the presence of pulmonary hypertension. 
In order to further clarify the additional diagnostic utility over echocardiography, two models 
were compared. Linear regression using echo-RVSP alone gave R
2
=40.3 (p<0.0005). Repeating 
the model with echo-RVSP and the formula result (136-SpO2-0.25 x DLco % pred) has a better 
fit (R
2
=62.2, p<0.0005 for both echo-RVSP and formula result). Likelihood ratio test indicates 
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improvement of the model (p=0.0001). This demonstrates that the formula adds significantly 
more information than is available with echocardiography alone. 
Combination with Echocardiography 
Separate analysis was performed in 96 patients with echocardiography and pulmonary function 
tests contemporary to the right heart catheter. Both echocardiographic and formula results were 
converted to categorical variables: echocardiography using the guidelines (0 if RVSP<37 
mmHg, 1 if RVSP≥37 and ≤50 mmHg, 2 if RVSP>50mmHg) and the lung function formula (0 
if predicted mPAP<25, 1 if predicted mPAP 25-35, 2 if pred mPAP>35). Multivariable Logistic 
regression shows similar odds ratios for each increase in Formula category (odds ratio 3.9, 
p=0.003, CI 1.6-9.6) and Echo category (odds ratio 3.2, p=0.009, CI 1.3,7.5), and there is no 
interaction between the two scores (p=0.45 for interaction term). 
The PFT formula we have suggested can be combined with RVSP on echocardiography to give 
a simple score (formula category + echo category) between 0 and 4. This score has an area 
under the curve of 0.78 (0.70-0.87) for presence of pulmonary hypertension on right heart 
catheterisation. A score of 2 or more has a sensitivity of 80.6% (95% CI 64.0,91.8) and a 
specificity of 63.3% (49.9,75.4) for the presence of pulmonary hypertension. A score of 3 or 
more has a sensitivity of 28.3% (95% CI 17.5,41.4) and a specificity of 97.2% (95% CI 
85.5,99.9) for the presence of pulmonary hypertension. 
In a typical scleroderma population with a prevalence of pulmonary hypertension of 12%, a 
score below 2 will be reassuring with an associated prevalence of PH 5.8% (4.1,8.4), a score of 
2 will be concerning, with an associated prevalence of PH of 28% (15,46.1) and a score of 3 or 
4 is predictive of PH with a prevalence of 58.2% (16.2,90.9). This simple score allows 
combination of echocardiography with pulmonary function testing and facilitates decision 
making in patients with equivocal results in either test. 
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Validation of the Pulmonary Function Test Formula in non-
Scleroderma Connective Tissue Disease 
We then tested the formula in 53 patients with non-SSc CTD who underwent their first RHC at 
the same time in our institution.  
Application of the formula in this population gave an AUC of 0.64 (95% CI 0.45,0.84). Using a 
threshold of 25mmHg the sensitivity was 92.9%, specificity 18.2%, positive likelihood ratio 1.1, 
negative likelihood ratio 0.4. The high sensitivity is encouraging but the positive predictive 
value will depend on the prevalence of pulmonary hypertension in the population under 
consideration. 
Performance of Other Proposed Formulae 
In our entire study population (n=386) we compared performance of our formula and 
recommended thresholds with that of others, and provide p values for significance of difference 
in areas under the curve between our own formula and the others [Table 3]. 
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Table 3. Comparison of performance of our formula to other formulae for predicting mPAP based on 
pulmonary function data in all 386 patients 
 Area under 
curve 
(95% CI) 
Threshold Sensitivity Specificity P value 
Our formula 0.75 (0.70,0.80) >25 91.0% 35.0%  
  >35 29.2%   95.1%  
ILD formula
5
 0.71 (0.66,0.76) >25 29.6% 94.4% 0.075 
FVC/DLCO 0.66 (0.60,0.71) >1.4 89.3% 22.4% <0.001 
  >2 55.6% 67.1%  
DLCO/VA 0.70 (0.65,0.76) <70% 79.0% 46.9% 0.082 
  <60% 58.4% 71.3%  
Discussion 
In our large cohort of patients with systemic sclerosis we have derived and validated a formula 
to improve detection of pulmonary hypertension using pulse oximetry and diffusion of carbon 
monoxide: Predicted mPAP = 136 – SpO2 – 0.25 x DLCO% predicted. A simple nomogram may 
be used to quickly establish if a patient is in the low risk (predicted mPAP < 25 mmHg), 
average risk (predicted mPAP 25-35mmHg) or high risk (predicted mPAP > 35 mmHg) 
categories (Figure 3). 
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Figure 3. Nomogram showing which patients with systemic sclerosis have predicted mean pulmonary artery 
pressures below 25 mm Hg (low risk), 25-35 mm Hg (average risk) or above 35 mm Hg (high risk) based on 
DLCO and oxygen saturation. 
 
Low risk patients are unlikely to have pulmonary hypertension (prevalence 4%, 95% CI 2-9). 
High risk patients are likely to have pulmonary hypertension (prevalence 63%, 95% CI 19-93). 
In the average risk patients the results do not markedly change the pretest probability of 
pulmonary hypertension (prevalence 11%, 95% CI 9-14, compared to background assumed 
prevalence in the group of 12%). We suggest that patients at high risk should be considered for 
right heart catheterization while those at low risk can be reassured, and a longer follow-up 
period may be considered. In the intermediate group, management is unchanged. 
Our analysis was geared particularly to establishing the diagnostic value of pulmonary function 
tests in detecting pulmonary hypertension in systemic sclerosis. In this ‘real life’ cohort, 
different causes of pulmonary hypertension were diagnosed, including pulmonary hypertension 
associated with respiratory disease (group 3) and cardiac disease (group 2) as well as pulmonary 
arterial hypertension (group 1). Diagnosis of pulmonary hypertension is important in all 
patients. In patients with interstitial lung disease, those with pulmonary hypertension have a 
worse prognosis than those without, and diagnosis aids in counseling and planning. Pulmonary 
hypertension due to left heart disease can and should be treated and is associated with an 
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adverse prognosis where pulmonary hypertension is present. Thus, detection of pulmonary 
hypertension is important in all patients in systemic sclerosis. 
The formula explains only 23% of the variability in pulmonary artery pressures, which is 
reflected in the wide confidence intervals for agreement between predicted and measured 
pulmonary artery pressures. However, the receiver operating characteristics show that it 
performs well at predicting presence or absence of pulmonary hypertension. 
Echocardiography is widely used as the primary non-invasive test of pulmonary artery 
pressures. Analysis of echocardiographic data in our patients has shown that the two tests 
provide complementary information and that information derived from pulmonary function tests 
is as predictive as echocardiography. Our analysis combining echocardiography with pulmonary 
function tests shows a high prevalence of pulmonary hypertension in patients with a high result 
for either or an equivocal result for both. Patients with an equivocal result in one test and a 
reassuring result in the other are less likely to have pulmonary hypertension. 
We have shown that in patients with anti-centromere antibodies the formula performs 
particularly well. The difference in antibody subgroups may be partially explained by a higher 
prevalence of interstitial lung disease in patients with anti-scleroderma-70 antibodies. However, 
correcting for FVC does not improve the model. The differences may be due to lung changes 
which are not reflected in the forced vital capacity, or FVC may be reduced in patients with 
PAH who are breathless. 
Our analysis shows that disproportionate reduction in oxygen saturation for a given DLCO % 
predicted is seen in pulmonary hypertension. This mirrors the findings of Zissman et al in 
idiopathic interstitial lung disease.
15
 It seems that oxygen saturation and DLCO are influenced by 
somewhat different physiological components each of which impact on pulmonary artery 
pressures. DLCO correlates with extent of fibrosis on HRCT in systemic sclerosis.
16
 Hypoxaemia 
may relate in addition to severe vascular intimal remodeling and obliteration causing 
ventilation-perfusion mismatch and to shunting through a patent foramen ovale. Pulmonary 
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vasculopathy may be associated with impaired hypoxia induced vasoconstriction which 
profoundly amplifies ventilation-perfusion mismatch causing disproportionate hypoxia.
17
  
Our results can be compared with other reported studies. A high ratio of FVC to DLCO% 
predicted was associated with pulmonary arterial hypertension in 49 patients with systemic 
sclerosis,
18
 and a low DLCO/VA was associated with subsequent development of pulmonary 
hypertension in 110 patients in France.
19
 In patients with idiopathic pulmonary fibrosis, a 
formula based on pulmonary function tests and oxygen saturation can help detection of 
pulmonary hypertension.15 
Echocardiography is a recommended tool for the non-invasive diagnosis of pulmonary 
hypertension.
20,
14 However, echocardiography cannot assess lung disease and is not always 
technically possible. Even when performed within one hour of the right heart catheter there is 
only moderate agreement between echocardiography and right heart catheter pulmonary artery 
pressures.
21
 Patients with scleroderma require regular pulmonary function tests including DLCO 
to screen for interstitial lung disease.
22,23,24
 Using our formula, these tests can be used to detect 
patients more likely to have pulmonary hypertension, making this a more cost effective test. 
Strengths of our study include the large patient cohort, the inclusion of clinical diagnoses, 
serology and oxygen saturation and the completeness of right heart catheter data. In addition, we 
have been able to derive and validate our formula in separate but comparable patient groups, 
and to test it in a different patient population with connective tissue diseases other than 
scleroderma. 
Our study had limitations. The prevalence of pulmonary hypertension in the cohort was 63%, 
which indicates that the current decision rules for selection of patients for right heart catheter 
are fairly effective. Use of this formula would allow for further refinement. Patients without 
PFT data were excluded from the study. However, this is unlikely to have affected the results 
because the patients who were excluded had similar incidence and severity of PH. We have not 
included high resolution CT data and have used FVC % predicted to distinguish patients with 
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pulmonary arterial hypertension from pulmonary hypertension due to lung disease. We have 
shown subgroup analysis for those with preserved FVC and for patients with normal wedge 
pressures. It is not known whether lung disease which does not affect lung function may cause 
secondary hypertension. We did not have echocardiographic data for most patients and there 
may have been selection bias in the patients who had echocardiography repeated at our hospital, 
so the comparison to echocardiography was limited and should be repeated in a prospective 
cohort. 
Further work should explore combining pulmonary function test data with other non-invasive 
information such as symptoms, six minute walking distance and brain natriuretic peptide levels. 
Prospective validation of this formula may be possible in patients recruited to the DETECT 
study, a prospective, observational, cohort study in scleroderma patients to evaluate screening 
tests.
25
 Other important initiatives including the Pulmonary Hypertension Registry of 
Scleroderma (PHAROS) and the ItinerAIR Scleroderma Study Group are furthering our 
understanding of the clinical utility of non-invasive testing for earlier detection of pulmonary 
hypertension. 
In conclusion, we have shown that pulmonary function tests and  pulse oximetry are useful in 
screening for pulmonary hypertension, providing information which is complementary to 
echocardiography. Using this simple formula may assist in interpretation of pulmonary function 
tests performed as routine screening in patients with systemic sclerosis and in better selection of 
patients for right heart catheterization. 
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Chapter 2. Combining non-invasive 
tests to diagnose pulmonary 
hypertension 
Schreiber BE, Valerio CJ, Handler C, Keir G, Wells AU, Denton CP, Coghlan JG.  
A new formula to Predict Pulmonary Artery Pressures in Patients with Connective Tissue 
Disease based on Echocardiography, NTproBNP and O2 Saturation. 
Oral presentation. ACR, Atlanta, November 2010 
Abstract 
Introduction 
Pulmonary Hypertension (PH) is an important complication of connective tissue disease (CTD). 
Diagnosis is confirmed by right heart catheter (RHC) but no single non-invasive test accurately 
predicts PH. To improve selection of patients for RHC, we analysed the relationship between 
non-invasive tests and mean pulmonary artery pressure (mPAP) at RHC and derived a new 
formula to predict PAP. 
Methods 
Retrospective analysis of patients with CTD undergoing a first RHC. In our database we have 
968 patients (811 SSc, 53 SLE, 15 RA, 42 UCTD, 8 MCTD, 12 DM, 7 PM, 6 Sjogrens, 3 
antiphospholipid syndrome, 3 vasculitis). We included for analysis NTproBNP and 
echocardiography if performed within 3 months of RHC and pulmonary function tests if done 
within 6 months. Pulse oximetry was measured at the time of the RHC. 
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Results 
Regression analysis of these variables individually against mPAP at RHC gave the following 
results: DLCO (n=469) gave R
2
=8.7, AUC=0.68; NTproBNP (capped at 300 pmol/litre to reduce 
the skewing effect of large values) with n=380, gave R
2
=31.5, AUC=0.74 and echo derived 
tricuspid valve gradient (n=165) gave R
2
=48.9, AUC=0.81. Capping NTproBNP gave similar 
results to a log transformation. 
Multivariable linear regression showed significant correlation with mPAP for Echo derived TV 
gradient (p<0.0005), capped NTproBNP and Oxygen (p=0.004). Addition of predicted DLCO, 
KCO, FVC, weight or height did not improve the fit. To reduce heteroskedasticity, oxygen was 
used categorically (1 if SpO2 >94%, 2 if 90-94%, 3 if <90%). Based on all 123 patients for 
whom we had NTproBNP, echo and SpO2 data, the derived formula is: 
Predicted mPAP = 8.37 +3.83 x Oxygen category + 0.328 x Echo derived Tricuspid Valve 
gradient + 0.032 x NTproBNP (capped) 
This formula had R
2
 of 60.3%.  
 
The area under the curve was 0.84 (95% CI 0.77-0.91). Using a threshold predicted mPAP of 25 
it has a sensitivity of 87.3%, specificity of 55.8%, positive LR of 2.0 and negative LR of 0.2. 
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Using a threshold predicted mPAP of 30, it has a sensitivity of 66.2%, specificity of 90.4%, 
positive LR of 6.9, negative LR of 0.4. 
Bland-Altman analysis showed a mean agreement of -0.6 (95% CI -16.4, 16.3) for difference 
between predicted and actual mPAP, although as seen in the figure, the 95% CI are tighter at 
lower predicted values.  
 
 
This compares favourably with echocardiography done within 1 hour of the RHC (Fisher MR et 
al, Am J Respir Crit Care Med. 2009). 
Conclusions 
This formula may help identify CTD patients requiring RHC. Patients with a formula predicted 
mPAP under 25 are unlikely to have PH, and those patients with predicted mPAP above 30 are 
very likely to have PH. 
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Introduction 
Pulmonary Hypertension (PH) is an important complication of connective tissue diseases, 
occurring in about 12% of patients with Systemic Sclerosis (SSc) and less commonly in other 
rheumatic diseases.13 Right heart catheterization (RHC) is the gold standard diagnostic test but 
it is invasive. European guidelines suggest use of echocardiographically estimated right 
ventricular systolic pressure (RVSP) based on tricuspid regurgitant jet maximal velocity (TR 
Vm) with three arbitrary categories: unlikely (RVSP<36), possible (RVSP 36-50) and likely 
(RVSP>50).14 It is not clear how echocardiography should be interpreted with respect to 
patients’ symptoms or to lung function tests. 
We have recently shown that a formula based on pulmonary function tests (predicted mPAP = 
136 - SpO2 - 0.25 x DLco% predicted) is associated with the presence of pulmonary 
hypertension in patients with systemic sclerosis.
26
 Other non-invasive measures such as 
functional class, six minute walking distance, NT-pro-BNP and pulmonary function tests have 
been shown to correlate with presence of PH on RHC. However, it is not known whether using 
a combination of non-invasive measures can predict the presence of PH better than using RVSP 
alone. Using a large database of patients with connective tissue disease who have undergone 
RHC, we sought to explore the optimal combination of non-invasive tests. 
Patients and Methods  
We analysed data from 152 patients with SSc who underwent a first RHC at a PH referral centre 
between 2005 and May 2010 and who had contemporary echocardiography (Royal Free 
Hospital, London, UK). 
The mean age was 59 years and 17% of the patients were male. 59% were found to have PH at 
RHC. Skin involvement was limited in 70% and diffuse in 30%. 
We analysed each of the non-invasive diagnostic tests in turn, to examine how informative each 
test is in predicting presence of PH using receiver operating characteristics. Correlation 
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coefficients of each parameter against mean pulmonary artery pressure (mPAP) were also 
calculated. 
We used correlation coefficients to examine the correlation between test result and mPAP on 
RHC. Receiver operating characteristics were assessed and area under the curve was calculated 
to provide an estimate of the diagnostic utility of the test in establishing presence or absence of 
PH. Logistic regression was used to identify combinations of variables which predict presence 
of PH. We then applied the findings to calculate positive predictive values in a typical SSc 
population with a prevalence of PH of 12%. 
Results 
We first analyzed the relationship between individual variables and the presence of PH, using 
receiver operating characteristics and univariable logistic regression (Table 1). In our pulmonary 
hypertension enriched population of 100 patients with echocardiography suggesting PH is 
“unlikely” according to current guidelines (RVSP<36), 42 had pulmonary hypertension, 
highlighting the high rate of false negatives with this test. 
Univariate analysis was performed for baseline demographic, pulmonary function tests, six 
minute walking distance, NTproBNP, functional class, and echo derived RVSP against 
pulmonary hypertension at RHC. 
Table 1. Univariable Analysis of variables associated with the presence of pulmonary hypertension 
 Odds ratio 95% CI P value  
Age 0.99 0.96,1.02 0.358 
Gender 1.02 0.44,2.40 0.959 
6MWD 0.99 0.99,0.10 0.011 
O2 SATn 0.87 0.77,0.98 0.021 
38 
 
DLco %  0.95 0.92,0.98 <0.0005 
PFT formula 1.16 1.06,1.26 0.001 
WHO FC 4.62 2.21,9.64 <0.0005 
NT-proBNP 1.004 1.001,1.008 0.009 
ECHO rvsp 1.10 1.06,1.14 <0.0005 
 
We repeated analysis of the non-invasive diagnostic tests described individually above using 
logistic regression. On multivariate analysis, the echo category, functional class category and 
pulmonary function test category were independently predictive of presence of pulmonary 
hypertension (Table 2). 
Table 2. Multiple Variable Logistic Regression using Categorical values for functional class, 
echocardiographic RVSP and NT-pro-BNP 
 Values Odds ratio CI P value 
Functional Class 
category 
0: FC I/II 
1: FC III/IV 
4.19 1.1, 16.2 0.037 
Echo category 0 : RVSP <36 
1 : RVSP 36-50 
2 : RVSP >50 
3.94 1.3, 11.7 0.014 
PFT formula 
(136-SpO2-
0.25*DLco %) 
0: <25 
1: 25-35 
2: >35 
3.39 1.0, 11.4 0.048 
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We therefore generated a score to calculate the combined risk based on these variables: 
Table 3. Components of score 
Score 0 1 2 
PFT formula 
(136-SpO2-0.25xDLco% 
predicted) 
<25 25-35 >35 
Echo RVSP <36 36-50 >50 
Functional class I,II III,IV 
 
The higher the score the greater the proportion of patients with pulmonary hypertension (odds 
ratio 3.8, p<0.0005, 95% CI 2.0-7.1) [Figure 1]. 
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These fall into three groups: PH unlikely (score of 0), PH possible (score of 1-2) and PH likely 
(score of 3-5). These categories form the Royal Free Score (RFS). 
RFS 0 1-2 3-5 
No PH 8 14 2 
PH confirmed 1 20 36 
 
We are thus able, using a combination of functional class assessment, echocardiography and 
pulmonary function tests, to exclude pulmonary hypertension in patients with score 0 
(negative predictive value 88.9%, 95% CI 51.8-99.7%) and to diagnose pulmonary 
hypertension in those with score of 3-5 (positive predictive value 94.7%, 95% CI 82.3-
99.4%). 
This score is more tightly associated with pulmonary hypertension than the current 
echocardiograpic guidelines (AUC 0.83 for RFS compared to 0.73 for TR Vmax, p=0.048 for 
comparison) (Figure 2). 
[Figure 2] 
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The score was derived in a PH enriched cohort with a prevalence of PH of 61% and would be 
applicable to a similar population seen in pulmonary hypertension clinics and selected for right 
heart catheterisation. We can extrapolate to calculate positive and negative predictive values if 
this score is applied to screening investigations in a typical SSc population with a prevalence of 
PH 12%. If used as a screening test in a general systemic sclerosis cohort with a prevalence of 
pulmonary hypertension of 12%, prevalence of PH would be 0.7% (0.1-5.1%) in those with 
RFS 0, 16.9% (12.8-22.1%) in those with RFS 1 and 50.8% (21.3-79.8%) in those with RFS 2. 
Thus in a screening setting in a general SSc population, patients with a RFS 0 can be reassured, 
while those with a score of 2 should be considered for RHC. Patients with a score of 1 would 
remain under closer follow up, perhaps with six monthly review. 
Summary 
Our findings suggest that selection of patients for RHC can be improved by integration of 
echocardiography with other non-invasive measures, specifically pulmonary function tests and 
functional class assessment. This score combines anatomical and physiological information with 
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functional assessment and may enable better integration of currently disparate non-invasive 
testing in order to better select patients for RHC. 
Screening programs allow for detection of patients with milder pulmonary hypertension.
27
 
However, screening programs based on echocardiography alone have found high false positive 
and false negative rates. The UNCOVER study showed that echocardiography suggested 
pulmonary hypertension was likely (RVSP>50mmHg) in 22.5% of patients with systemic 
sclerosis or mixed connective tissue disease in community rheumatology practices.
28
 Previous 
studies in SSc have evaluated the reliability of prospective screening of patients with SSc based 
on tricuspid regurgitation velocity of 2.5-3.0 m/s in symptomatic patients (functional class II-
IV) or 3.0 m/s irrespective of symptoms. They found that 45% of cases of echocardiographic 
diagnoses of PH were falsely positive.
29
 The true incidence of false negative cases is not 
known.
30
 
By comparison, our findings suggest that pulmonary hypertension can be excluded in patients 
with normal echocardiography, low risk pulmonary function tests (136-SpO2-0.25*DLco% 
predicted<25) and little or no breathlessness (FC I/II). The study has limitations due to its 
retrospective nature. In addition, we have analysed data on patients selected for right heart 
catheterization. It should therefore be seen as hypothesis generation for testing in a prospective 
data set. Validity can be explored in other large well characterized scleroderma cohorts and the 
ongoing DETECT study will offer an opportunity for prospective validation. 
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Chapter 3. Borderline pulmonary 
hypertension – What predicts 
progression in systemic sclerosis? 
Schreiber BE, Valerio CJ, Handler C, Denton CP, Coghlan G. Predictors of Progression to 
Pulmonary Hypertension in Systemic Sclerosis. Abstract no 11-3526. EULAR, London, May 
2011. 
Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary 
gradient predicts risk of developing pulmonary hypertension. Valerio CJ, Schreiber BE, 
Handler CE, Denton CP, Coghlan JG. Arthritis Rheum. 2013 Apr;65(4):1074-84. 
Abstract 
Background 
In patients with systemic sclerosis (SSc) who undergo right heart catheterisation (RHC) and are 
not found to have pulmonary hypertension (PH), it is not clear which parameters predict future 
progression to pulmonary hypertension. 
Objectives 
We sought to clarify which haemodynamic parameters predict future progression to PH in 
patients with SSc. 
Methods 
Data on all RHCs in a PH referral centre were collected prospectively. Criteria for first RHC 
were based on standard screening algorithms incorporating clinical and laboratory 
assessment. We analysed all patients with SSc who underwent RHC, to find predictors of 
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progression to PH (n=340). Logistic regression was used to calculate predictors of future PH 
and Kaplan-Meier survival analysis to calculate difference in outcome between groups. 
Results 
For the 340 patients with SSc who underwent repeat RHC, mean age was 58.6 years, 80% were 
female and 77% had limited scleroderma.  
Data from the first RHC showed: 45 normal mPAP (≤ 20mmHg, mean PVR 163 dynes.s.cm-5), 
49 borderline (mPAP 21-24, mean PVR 220), 65 mild PH (mPAP 25-29, mean PVR 280) and 
181 with mod-severe PH (mPAP ≥ 30, mean PVR 663). 
Of patients with normal mPAP, 30% progressed in 5 years, compared to 58% of those with 
borderline values. Mean time to progression was 74 months (95% CI 67.9-) in those with 
normal mPAP at baseline and 41 months (95% CI 26.1-67.9) in those with borderline mPAP at 
baseline (p=0.02 by log-rank for survival free of PH). 
Univariate logistic regression showed poor correlation with baseline functional class, presence 
of fibrosis, age, gender, disease subtype (limited vs diffuse), body surface area, heart rate, right 
atrial pressure, and cardiac output, CO. There was significant correlation with mPAP (p=0.03) 
and pulmonary vascular resistance, PVR (p=0.02) and a trend with pulmonary capillary wedge 
pressure, PCWP (p=0.07).Mean mPAP in patients who progressed to PH was also higher than in 
patients who did not (21.1 vs 19.8, p=0.03). 
Patients with initial mPAP above 20 had a trend towards progression to PH (odds ratio 2.0, 95% 
CI 0.9-4.7, p=0.11). The trend loses significance when adjusted for high PVR (p=0.48) while 
high PVR remains significant (odds ratio 3.1, p=0.02). High PVR is a particularly strong 
predictor amongst patients without lung fibrosis (OR 7.4, 95% CI 2.2-25.5, p=0.001). 
Kaplan-Meier survival analysis to show proportion of patients surviving without progression to 
PH was performed. There is a clear divergence between those with PVR >200 and those <200 
dynes.s.cm
-5
, (p=0.003 by log-rank test). 
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Annual progression to PH is 18.7% in those with PVR>200 and 7.4% in those without giving an 
incidence rate ratio of 2.5 (95% CI 1.2-5.6) for those with PVR>200 compared to those with 
low PVR.  
Conclusions 
In patients with systemic sclerosis who do not have pulmonary hypertension on right heart 
catheterisation, patients with PVR above 200 dynes.s.cm
-5
 are at high risk of future progression 
to pulmonary hypertension. Repeat RHC should be considered in these patients. 
 
Introduction 
The definition of pulmonary hypertension continues to hinge on a single threshold of mean 
pulmonary artery pressure. However, the disease is clearly a continuum of increasing pulmonary 
vascular resistance causing a compensatory increasing pulmonary artery pressure. It has long 
been established that normal resting pulmonary artery pressures are under 20 mmHg, in fact 
they are more like 14.0 ± 3.3 mmHg.
31
 20 mmHg represents a level 2 standards of deviation 
above the mean. This clearly leaves an interval of 21-24 where there is an abnormal pulmonary 
artery pressure not diagnostic of pulmonary hypertension. Little is known about the prognostic 
meaning of such borderline results. 
Methods 
For these analyses we reviewed retrospectively all patients with connective tissue diseases who 
underwent a first right heart catheterization at our Institution. Inclusion criteria were: 
Connective tissue disease diagnosis, no clinical diagnosis of pulmonary fibrosis at the time of 
right heart catheterization, FVC >70% where available and pulmonary capillary wedge pressure 
≤15mmHg. Mortality data was censored at 5 years follow up. Pulmonary function tests were 
included if performed within six months of right heart catheterization. 
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Patients with any underlying condition were included. The present analysis considered only 
those patients who had more than one right heart catheterisation. The right heart catheterisations 
were performed for clinical indications including unexplained breathlessness, unexplained low 
transfer of carbon monoxide, evidence of pulmonary hypertension on echocardiography 
(tricuspid regurgitant maximal velocity > 3.0 m/s). 
636 patients with connective tissue disease underwent right heart catheterization. We grouped 
the patients by the mean pulmonary artery pressure at the initial right heart catheter study. 
We classified patients into four groups based on the mPAP. Group 0 (normal) had mPAP≤20, 
Group 1 (borderline) had mPAP 21-24, Group 2 (mild PH) had mPAP 25-29 and group 3 
(moderate-severe PH) had mPAP≥30. 
Group 0 patients are younger than Group 1-3 patients (p=0.02) but there was no difference 
between groups 1, 2 and 3 (p=0.29 by ANOVA). There was no difference in gender between the 
groups (p=0.63 by ANOVA). Results are shown in figure 1. 
Results 
539 patients had repeat right heart catheterisations. The average age was 58.5 ± 13.3. 76.6% 
were female. 63.1% had systemic sclerosis (340 patients, 263 LcSSc, 77 DcSSc). Pulmonary 
fibrosis was present in 29% of patients. Pulmonary hypertension (mPAP ≥ 25 mmHg) was 
diagnosed in 80.9% of those who had subsequent right heart catheterisations. Of these patients 
340 patients had systemic sclerosis. Of them, 36% had pulmonary fibrosis. 
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Figure 1. Baseline characteristics on right heart catheter of patients with connective tissue disease 
 Definition n= Mean 
mPAP 
Mean 
PVR 
Cardiac 
Output 
Mean 
Dlco % 
(n) 
Age 
Group 0 mPAP < 21 176 17.0 144.6 4.9 58.4 (62) 58.3 
Group 1 mPAP 21-24 102 22.2 199.7 5.1 54.1 (41) 61.2 
Group 2 mPAP 25-29 95 26.8 274.7 5.1 49.7 (42) 62.2 
Group 3 mPAP ≥ 30 263 45.2 772.7 4.3 40.7 
(115) 
60.1 
 
As expected, the bulk of the patients had scleroderma as their connective tissue disease. There is 
a trend towards more patients with anti-centromere antibodies in Group 1 than in Group 0 
(p=0.08) but the proportion of patients with Scl-70 is similar in Group 1 and Group 0 (p=0.48). 
Figure 2. Connective tissue disease subtype and presence of ACA and ATA profiles 
 Scleroderma Centromere Scl-70 SLE 
Group 0 85.2% 41.8% 13.0% 8.0% 
Group 1 90.1% 58.1% 18.0% 0.0% 
Group 2 84.2% 67.3% 8.8% 6.3% 
Group 3 79.5% 67.2% 1.3% 8.0% 
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Haemodynamic profile 
Baseline PVR is higher with each subsequent group (p<0.00005 for each comparison). Cardiac 
output in similar in groups 0 and 1 (p=0.32) and groups 1 and 2 (p=0.94). There is no difference 
in cardiac output across groups 0-2 (p=0.52 by ANOVA). However, there is a clear difference 
between group 2 and group 3 (p<0.0005). Wedge pressures was higher in group 1 than group 0 
(p<0.0005), similar in groups 1 and 2 (p=0.32) and worse in group 3 than in group 2 (p=0.01). 
Figure 3. Average pulmonary capillary wedge pressure in each group 
 Mean wedge pressure Standard Error 95% CI for Mean 
Group 0 8.59 0.20 8.19-8.99 
Group 1 10.27 0.26 9.76-10.79 
Group 2 10.66 0.29 10.10-11.22 
Group 3 9.80 0.18 9.45-10.15 
 
We have only studied patients who had no clinical diagnosis of interstitial lung disease and with 
FVC > 70 % predicted where known. 
49 
 
Figure 4. Pulmonary function tests results in each group 
 Definition Patients with 
PFTs/Total 
(%) 
Mean 
FVC % 
Mean 
Dlco %  
Age 
Group 0 mPAP<21 62 / 176 (35) 99.9 58.4  58.3 
Group 1 mPAP 21-24 41 / 102 (40) 103.9 54.1  61.2 
Group 2 mPAP 25-29 42 / 95 (44) 98.6 49.7  62.2 
Group 3 mPAP ≥30 115 / 263 (44) 95.1 40.7 60.1 
 
FVC does not vary between groups 0,1 and 2 (mean 100.7 % predicted, p=0.31 by ANOVA) 
but is lower in group 3 than in groups 0,1 and 2 combined (p=0.008). There is a trend to lower 
DLco in group 1 than in group 0 (p=0.15), and for lower DLco in group 2 than in group 1 
(p=0.17). Group 2, however, is clearly lower than Group 0 (p=0.002) and there is a further clear 
drop between groups 2 and 3 (p=0.0002). 
Functional class was scored for most patients (n=567 of 636) at the time of right heart 
catheterization. Mean functional class in each group is shown in the figure. Functional class in 
groups 0 and 1 were similar (p=0.76). It was worse in group 2 than group 1 (p<0.0005) and 
worse in group 3 than group 2 (p<0.0005). 
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Figure 5. WHO Functional class by group 
 Mean functional class Standard Error 95% CI for Mean 
Group 0 2.32 0.06 2.20-2.44 
Group 1 2.29 0.07 2.16-2.43 
Group 2 2.73 0.06 2.61-2.84 
Group 3 3.07 0.04 2.99-3.15 
Haemodynamic progression at 1 year 
As regards the change in pulmonary vascular resistance (PVR), there is no statistical difference 
in absolute or proportional progression between groups 0, 1 and 2 (p=0.50 and p=0.55 by 
ANOVA respectively). However, there is a clear difference between groups 0, 1 and 2 
combined and group 3 (p<0.0005 for absolute and proportional change). 
Figure 6. Change in PVR in one year 
 n= Baseline 
PVR 
1 year 
PVR 
PVR change 
(abs) 
P value (for 
comparison to 
baseline) 
PVR 
change (%) 
Group 0 10 162.6 179.4 16.8 0.43 11.4% 
Group 1 8 197 279.7 82.7 0.07 40.6% 
Group 2 34 295.5 363.0 67.5 0.02 24.3% 
Group 3 92 754.5 593.5 -161.1 0.08 -13.2% 
With regard to changes in mean pulmonary artery pressure, the absolute and proportional 
change in group 1 is not significantly different to that in group 0 (p=0.54 and p=0.46 
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respectively). However, group 3 clearly is different to groups 0,1 and 2 combined (p=0.0003 
and p=0.0008 respectively). 
Figure 7. Change in mPAP in one year 
 n= Baseline 
mPAP 
1 year 
mPAP 
mPAP 
change 
(abs) 
P value (for 
comparison to 
baseline) 
mPAP 
change (%) 
Group 0 11 18.4 33.5 +15.1 0.21 +81.6% 
Group 1 9 21.9 29.1 +7.2 0.009 +32.6% 
Group 2 35 26.7 30.1 +3.4 0.008 +12.7% 
Group 3 99 45.0 42.9 -2.2 0.053 -3.5% 
 
Survival 
Unadjusted relative risk of survival compared to Group 0: 
 
0.1 1 10 100
Relative Risk of Mortality
compared to Group 0 (mPAP<21, n=176)
Group 1 (mPAP 21-24, n=102)
Group 2 (mPAP 25-29, n=95)
Group 3 (mPAP >=30, n=263)
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There is a clear trend towards worse survival in Group 1 than in Group 0 (p=0.15), and survival 
is clearly worse in group 2 than group 0 (p=0.03) and dramatically worse in group 3 than group 
0 (p<0.0005). 
In group 3, median survival is 42 months (95% CI for mean 31-48), in group 2 the median 
survival is 90 months (95% CI for mean starts at 64, upper limit not reached). 95% CI for 
median survival in group 0 is 101 months and in group 2 is 118 months. Median survival has 
not been reached in either group. 
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Survival adjusted for age and gender 
 
Interestingly, after adjustment for age and gender, there was no trend at all to difference in 
survival between Group 1 and Group 2 (p=0.99). There is still a weak trend to worse survival in 
Group 1 compared to Group 0 (p=0.16) and a strong trend to worse survival in Group 2 
compared to Group 0 (p=0.051). Survival in Group 3 remains clearly worse than in any other 
group. These findings suggest that the difference in age and gender across the groups may 
account for some of the differences in survival among groups 0, 1 and 2, and that the 
significance of borderline mPAP on survival should therefore be interpreted with caution. 
Sensitivity analyses 
Mean PVR in group 1 is 201.3. Survival is no worse in those in Group 1 with PVR≥200 than 
those with PVR <200 (HR 0.90, 95% CI 0.26,3.13). Those with high PVR have similar FVC % 
predicted to those with low PVR (p=0.79) but lower DLCO (62.3%, n=17 compared to 48.2%, 
n=24, p=0.004). 
Patients in Group 1 with anticentromere antibodies have similar survival to those without after 
adjustment for age and gender (HR 1.38, 95% CI 0.14, 13.48). 
0.1 1 10
Relative Risk of Mortality
compared to Group 0 (mPAP<21, n=176)
adjusted for age and gender
Group 1 (mPAP 21-24, n=102)
Group 2 (mPAP 25-29, n=95)
Group 3 (mPAP >=30, n=263)
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Indicators of Progression to Pulmonary Hypertension 
We compared baseline data in patients with systemic sclerosis who did not have pulmonary 
hypertension on initial right heart catheterisation (n=94) and who subsequently progressed to 
pulmonary hypertension (n=35) to those who did not progress (n=59). This shows that patients 
with higher pulmonary artery pressures and pulmonary vascular resistance are more likely to 
progress. Subgroup analysis is shown for patients without pulmonary fibrosis or raised 
pulmonary capillary wedge pressure at the time of initial right heart catheterisation (of whom 21 
progressed and 33 did not).   
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Comparison of Mean baseline values in patients with systemic sclerosis without pulmonary hypertension on 
initial right heart catheterisation who do progress to pulmonary hypertension on subsequent right heart 
catheterisation to those who do not 
 Patients who did 
not progress 
(n=59) 
Patients who did 
Progress (n=35) 
P value P value in those 
without 
pulmonary 
fibrosis or 
raised wedge 
pressure 
Age (years) 59.3 (56.0-62.6) 57.9 (54.2-61.5) 0.56 0.84 
Gender 81.3% female 77.1% female 0.63 0.97 
Body Surface 
area (m
2
) 
1.68 (1.63-1.73) 1.73 (1.66-1.79) 0.28 0.89 
Functional class 2.4 (2.2-2.6) 2.3 (2.0-2.5) 0.48 0.50 
Pulmonary 
fibrosis 
(prevalence) 
40.4% 33.3% 0.51 N/A 
Heart rate (bpm) 75.7 (71.4-79.9) 78.5 (73.5-83.5) 0.41 0.74 
Right atrial 
pressure (mmHg) 
5.0 (4.5-5.5) 4.7 (3.8-5.5) 0.47 0.85 
Mean PA 
pressure (mmHg) 
19.8 (19.0-20.5) 21.1 (20.2-22.0) 0.03 0.03 
Pulmonary 
capillary wedge 
pressure (mmHg) 
9.7 (9.0-10.4) 8.5 (7.4-9.6) 0.07 0.28 
Pulmonary 
vascular 
2.24 (2.00-2.48) 2.67 (2.43-2.92) 0.02 0.007 
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resistance (Wood 
units) 
Indicators of Progression to Pulmonary Hypertension 
In patients without pulmonary hypertension on the initial RHC (groups 0 & 1), Cox proportional 
hazards analysis was performed to determine which variables are associated with progression to 
pulmonary hypertension within 5 years. Univariate analysis was performed in these 102 
patients, and in the subset with SSc: 
57 
 
Univariate Cox Proportional Hazards analysis of association of variables with progression to pulmonary 
hypertension based on initial right heart catheterisation 
Variable Hazard ratio (95% 
CI) 
P value in SSc 
patients 
Age 0.99 (0.96-1.02) 0.57 
Gender 0.71 (0.31-1.61) 0.41 
Functional class 1.01 (0.60-1.72) 0.96 
Subtype 
(diffuse=0, 
limited=1) 
0.55 (0.23-1.29) 0.17 
Body Surface area 6.53 (0.92-46.62) 0.06 
Heart rate 1.03 (1.00-1.05) 0.03 
Right atrial pressure 0.99 (0.82-1.20) 0.96 
Systolic PA pressure  1.11 (1.03-1.21) 0.01 
Diastolic PA 
pressure 
1.16 (1.02-1.32) 0.03 
Mean PA pressure 1.27 (1.07-1.51) 0.005 
Cardiac output 1.14 (0.86-1.53) 0.36 
Arterial saturation 1.00 (0.83-1.20) 1.00 
PA saturation 0.99 (0.92-1.06) 0.71 
Pulmonary vascular 
resistance (Wood 
units) 
1.52 (1.01-2.30) 0.046 
Pulmonary capillary 
wedge pressure 
0.90 (0.77-1.05) 0.17 
 
We found that age, gender, disease subtype (limited vs diffuse), baseline functional class, 
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presence of fibrosis, body surface area, heart rate, right atrial pressure, and cardiac output were 
poorly associated with progression to PH. 
Higher mPAP (p=0.03) was associated with subsequent progression to pulmonary hypertension. 
Mean mPAP in patients who progressed to PH was higher than in patients who did not (21.1 vs 
19.8, p=0.03). 
Higher PVR also correlated strongly with progression to pulmonary hypertension (p=0.02). 
These variables were looked at categorically. mPAP was taken as normal or borderline 
(mPAP≤20 or 21-24) and PVR as below or above mean (200 dynes.s.cm-5). Presence of 
borderline mPAP (21-24) was associated with a trend towards progression to PH (odds ratio 2.0, 
95% CI 0.9-4.7, p=0.11). The trend loses significance when adjusted for high PVR (p=0.48) 
while high PVR remains significant (odds ratio 3.1, p=0.02). High PVR is a particularly 
strongly associated with progression to PH amongst patients without lung fibrosis (OR 7.4, 95% 
CI 2.2-25.5, p=0.001). 
Kaplan Meier analysis shows a clear divergence between those with PVR >200 and those <200 
dynes.s.cm-5, (p=0.003 by log-rank test). 
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Kaplan-Meier survival analysis showing proportion of patients surviving without progression to PH 
categorized by baseline PVR (dynes.s.cm-5). 
 
Progression to PH over 5 years occured in 60% of those with baseline PVR ≥ 200 and 25% of 
those with baseline PVR under 200. High normal PVR was associated with an incidence rate 
ratio of 2.5 (95% CI 1.2-5.6) for development of PH within 5 years. 
In order to understand these patient groups we looked further at other characteristics of the 
groups without pulmonary hypertension at baseline, categorised by PVR. 
Furthermore, we looked at the distribution of normal and borderline values of both PVR and 
mPAP. 
 PVR<200 PVR>200 
mPAP < 20 149 47 
mPAP 20-24 89 86 
 
We then looked at differences between these two groups. We found that those with PVR > 200 
were older, more frequently female, and had significantly more pulmonary fibrosis than those 
with lower PVR at baseline. 
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 PVR<200 (n=237) PVR>200 (n=133) P value 
Age  56.1 62.3 <0.0001 
Gender  17.6% Male 6.8% Male 0.0003 
Systemic sclerosis  0.882 0.887 0.89 
SSc subtype  75% limited 85% limited 0.06 
Pulmonary Fibrosis  0.233 0.404 0.003 
Functional class  2.4 2.5 0.29 
mPAP  18.3 20.2 <0.0001 
6MWD  339m (n=39) 327m (n=21) 0.71 
NTproBNP  44 pmol/l (n=102) 68 pmol/l (n=42) 0.28 
Echo PASP  30.4 (n=54) 32.2 (n=18) 0.39 
Variables associated with Survival 
mPAP is not associated with survival on univariate analysis (p=0.16). In contrast, PVR is 
closely associated of survival. In analysis as a continuous variable each additional Wood Unit (1 
wood unit = 80 dynes.s.cm
-5
) is associated with a 61% increase in risk of mortality (HR 1.61 
[1.30-2.00] p<0.0005). In analysis as a categorical variable as above (PVR ≥200 vs PVR <200) 
there is a similar additional risk of HR 1.62 [0.97-2.69], p=0.065 on Cox Proportional Hazard 
analysis.  
We found a strong association between baseline PVR and survival, both for those patients with 
systemic sclerosis (p=0.06) and for all patients with connective tissue diseases (p=0.02). 
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Survival by PVR in all patients with connective tissue disease 
 
Survival by PVR in all patients with systemic sclerosis 
 
We tabulated the survival data to show the effect of baseline PVR out to 10 years in patients 
with connective tissue disease. 
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Years Proportion alive 
if baseline PVR < 200 
Proportion alive 
if baseline PVR ≥ 200 
1 year  97.3% (95% CI 94-99) 93.8% (95% CI 87-97) 
3 years  89.6% (95% CI 84-93) 82.8% (95% CI 73-89) 
5 years  77% (95% CI 68-84) 69.6% (95% CI 57-79) 
10 years  58.1% (95% CI 39-73) 30.4% (95% CI 8-57) 
 
Subgroup analysis shows that in patients with pulmonary fibrosis (n=170), PVR does not 
predict survival (p=0.90), nor does mPAP predict survival (p=0.20). 
3 Variable Model 
Having completed these analyses of single variables we proceeded to formulating a multivariate 
model to predict progression to pulmonary hypertension. Variables which showed some 
significance on univariate analysis (p<0.1) were carried forward to multiple variable analysis. 
Pulmonary artery pressures lose significance and drop out. Body surface area, heart rate and 
pulmonary vascular resistance remain independently highly significant (p≤0.02).  
Using categorical variables, patients were classified as having above or below mean values of 
body surface area (1.7m
2
), heart rate (77 beats per minute) and pulmonary vascular resistance 
(2.4 wood units, 192 dynes.s.cm
-5
, which we rounded to 200 dynes.s.cm
-5
). These mean values 
are between the mean of those patients who do and do not progress to pulmonary hypertension. 
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Cox proportional hazards analysis of indicators of progression to pulmonary hypertension 
 Hazard ratio Confidence 
intervals 
P value 
BSA ≥ 1.7m2 3.82 1.53-9.53 0.004 
Heart rate ≥ 77 bpm 3.54 1.52-8.24 0.003 
PVR > 2.5 Wood 
units 
(200 dynes.s.cm
-5
) 
3.56 1.49-8.49 0.004 
 
There is no interaction between these three variables. If body surface area is removed from the 
analysis the significance of the association with heart rate and PVR drop (to p=0.009 and 
p=0.017 respectively). Patients with BSA ≥ 1.7m2 have a similar heart rate to those with BSA 
<1.7 m
2 
(81.8 vs. 81.1, p=0.65). Patients with BSA ≥ 1.7m2 have a lower PVR than those with 
BSA <1.7 m
2 
(5.2 vs. 6.3 wood units, p=0.025). Patients with heart rate ≥77 beats per minute 
have a significantly higher PVR than patients with a heart rate < 77 beats per minute (6.6 vs. 4.2 
wood units, p=0.0001). 
A simple combined score was derived: 
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Scoring system for likelihood of progression to pulmonary hypertension in future based on initial right heart 
catheterisation in patients with systemic sclerosis 
 0 1 
Body surface area < 1.7m
2
 ≥ 1.7m2 
Heart rate < 77 bpm ≥ 77 bpm 
Pulmonary vascular 
resistance 
<2.5 wood units 
(<200 dynes.s.cm
-5
) 
≥ 2.5 wood units 
(≥ 200 dynes.s.cm-5) 
 
Distribution of scores in our patient cohort and the prevalence of progression at 3 years by initial score 
Score Number of patients 3 year progression 
(%) 
0 7 0% 
1 41 15% 
2 33 40% 
3 10 87% 
 
There was no statistically significant difference detected between score 0 (n=7) and score 1 
(n=31), p=0.22 by log-rank, but there was a clear difference between score 1 (n=41) and score 2 
(n=33), p=0.007 by log-rank, and between score 2 (n=33) and score 3 (n=10), p=0.03 by log-
rank. 
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Kaplan-meier survival analysis of patients with systemic sclerosis who do not have pulmonary hypertension on 
initial right heart catheterisation. the progression to pulmonary hypertension over time is shown stratified by 
a score which is a composite of 3 categorical variables based on body surface area, heart rate and pulmonary 
vascular resistance. 
 
Discussion 
In this study we explored how to interpret the findings in patients with systemic sclerosis who 
are subjected to right heart catheterisations and found not to have pulmonary hypertension. We 
have shown that patients with PVR above 200 dynes.s.cm
-5
 are 2.5 times as likely to progress to 
pulmonary hypertension and 2.2 times as likely not to survive over the subsequent five years. 
This finding has important implications. Firstly, it suggests that patients with higher PVR 
should have closer follow up, with consideration being given to repeat right heart catheterisation 
in these patients. Additionally, this may identify a group of patients who may ultimately benefit 
from prophylactic treatment. This is an unproven concept, but one which could be tested in a 
clinical trial as there is a well-defined high risk group. 
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Further, we have shown that in patients with systemic sclerosis who do not have pulmonary 
hypertension, a simple score based on body surface area, heart rate and pulmonary vascular 
resistance is useful in stratifying patients by the risk of future progression to pulmonary 
hypertension. 
This analysis is open to criticisms. Our group of patients were selected for repeat right heart 
catheterisation due to clinical concern. The rate of progression calculated in our cohort may 
therefore be higher than would be the case in a population not selected for repeated right heart 
catheterisation. 
The finding that higher body surface area is associated with a higher risk of progression to 
pulmonary hypertension is novel and requires explanation. The significance of the association 
was much higher on multiple variable analysis than on single variable analysis. And there may 
be complex interactions between the variables which we cannot unpick. We have separately 
looked at the association between body surface area and survival in patients with pulmonary 
hypertension (see also page 67).  Although patients with a larger body surface area tend to have 
a lower pulmonary vascular resistance, after adjustment for pulmonary vascular resistance a 
larger body surface area is associated with a higher risk of progression. This is a novel finding 
and will require validation in independent cohorts. 
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Chapter 4. Raised body mass index is 
associated with increased prevalence 
of connective tissue disease 
associated pulmonary hypertension 
and improved survival 
Schreiber BE, Dobarro D, Handler C, Keir G, Wells AU, Denton CP, Coghlan JG. 
Poster presentation, British Society of Rheumatology Annual Conference, Glasgow, 2012. 
Abstract 
Objectives 
It is not known whether obesity is associated with pulmonary hypertension in patients with 
connective tissue disease, nor whether it is a predictor of survival. 
Methods 
We performed a retrospective analysis of 417 patients with connective tissue disease who 
underwent right heart catheterization and pulmonary function testing. We explored the 
association of body mass index to the diagnosis on right heart catheterization and whether 
survival in patients with pulmonary hypertension was associated with obesity (BMI>30kg/m2). 
Results 
Post-capillary pulmonary hypertension was diagnosed in 15% of obese patients and in 8% of 
non-obese patients (p=0.048). The incidence of pulmonary arterial hypertension did not differ. 
Obese patients had worse functional class, higher right atrial and pulmonary capillary wedge 
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pressures, higher cardiac output and tended to have higher mean pulmonary artery pressures 
(31.8 mmHg compared to 29.9 mmHg, p=0.052). 
Amongst patients with pulmonary hypertension, survival was significantly better in obese 
patients (hazard ratio 0.47, p=0.020, 95% CI 0.25,0.89). Amongst patients with pulmonary 
arterial hypertension, a trend to improved survival was still seen in obese patients. 
Conclusions 
In a pulmonary hypertension centre, obese patients selected for right heart catheterization were 
more likely to have pulmonary hypertension, particularly post-capillary pulmonary 
hypertension. However, survival in obese patients with pulmonary hypertension is overall better 
than survival in non-obese patients. Further work is required to better understand the underlying 
reasons for these associations. 
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Introduction 
Obesity is known to impact on heart and lung disease, but its role in pulmonary hypertension 
has not been clarified. Using a large clinical cohort of patients with connective tissue disease 
referred to a pulmonary hypertension service, we investigated the relationship between BMI 
(body mass index) and cardiopulmonary findings, including lung function tests and pulmonary 
haemodynamics. We explored whether obesity was associated with an increased prevalence of 
pulmonary hypertension. Lastly, we researched the association between obesity and survival in 
patients with confirmed pulmonary arterial hypertension. 
Methods and Materials 
We retrospectively reviewed a prospectively collected single centre database of patients with 
connective tissue disease who were assessed in a regional Pulmonary Hypertension centre with 
right heart catheterisation between January 1999 and April 2010.  
The patients underwent assessment with lung function tests within three months of a diagnostic 
right heart catheterisation. Heart rate, systolic and diastolic blood pressure and oxygen 
saturation were recorded at the time of right heart catheterisation. At right heart catheterisation, 
right atrial pressure, pulmonary artery pressures and pulmonary capillary wedge pressure were 
recorded by Swan-Ganz catheter. The zero position was taken as the midpoint between the 
sternum and the spine. Left ventricular end diastolic pressure was measured if a reliable 
pulmonary capillary wedge tracing could not be obtained and if necessary to confirm elevated 
wedge pressures. Where left ventricular end diastolic pressure was used this was treated as 
equivalent to pulmonary capillary wedge pressure. Cardiac output was computed by repeated 
thermodilution, with three consecutive calculations within 10%. 
Weight, height and smoking status were recorded at the time of the pulmonary function test, 
which was performed within three months of the diagnostic right heart catheterisation. Data on 
baseline pulmonary function tests, weight and height were available for 417 of 1001 patients 
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and these patients were included in the analysis. Survival data was obtained from the National 
Health Service database in April 2010. 
Statistical analysis was performed using Stata
®
 (StataCorp LP, Texas) version 10.0. Distribution 
of variables was assessed graphically. The distribution of variables was assessed graphically. 
Normally distributed variables were compared using t-test, non-parametric variables were 
compared using the Mann-Whitney test, and categorical variables using Chi squared. Kaplan-
Meier curves were used for survival analysis, with the log-rank test for comparing survival 
between groups. 
Results 
Of the 417 patients, 79 (18.9%) were obese (BMI≥30) and 338 (81%) were not. Only 5 patients 
had BMI>40. The distribution of BMI in the 417 patients is shown in Figure 1, and baseline 
characteristics in Table 1. 
Figure 1. Distribution of body mass index in the 417 patients 
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Table 1. Comparison of baseline characteristics between obese and non-obese patients 
 Not obese 
(BMI<30) 
n=338 
Obese 
(BMI≥30) 
n=79 
Significance of 
difference 
(p value) 
Age 58.8 55.8 0.049 
Gender 20.1% 15.1% 0.318* 
SSc Diagnosis 89.6% 82.2% 0.067* 
Functional class 
(I/II/III/IV) 
14/80/157/39 
Mean 2.76 
0/10/50/8 
Mean 2.97 
0.014* 
Six minute walking 
distance 
268.2m 
n=130 
266.9 
n=35 
0.956 
FVC (litres) 2.38 (0.86) 2.17 (0.82) 0.047 
FVC % predicted 81.4% 75.7% 0.076 
FEV1 % predicted 74.7% (21.9) 69.2% (19.1) 0.041 
FEV1/FVC 0.78 (0.11) 0.78 (0.10) 0.971 
Proportion with 
FEV1/FVC <70% 
pred 
21.5% 21.8% 0.951 
DLCO % predicted 43.5% (16.5) 45.9% (18.0) 0.270 
Smoker 
(never/past/current) 
198/114/14 42/29/3 0.857* 
Heart rate 82.0 (15.0) 82.8 (16.2) 0.66 
Systolic BP 137.6 (25.9) 137.9 (24.5) 0.936 
Diastolic BP 73.4 (12.1) 76.3 (13.4) 0.068 
RA pressure 6.8 (5.2) 7.5 (3.8) 0.010 
PA systolic pressure 48.2 (21.3) 49.8 (18.7) 0.017
+
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PA diastolic pressure 17.7 (9.0) 19.2 (7.4) 0.029
+
 
PA mean pressure 29.9 (13.0) 31.8 (11.5) 0.052
+
 
Proportion with PH 
(mPAP≥25) 
56.8% (n=338) 73.4% (n=79) 0.007 
Proportion with 
precapillary PH 
(mPAP≥25 and 
PCWP≤15) 
48.8% 58.2% 0.132 
Proportion with post-
capillary PH 
(mPAP≥25, 
PCWP>15) 
8.0% 15.2% 0.048 
Proportion with PAH 
(mPAP≥25, 
PCWP>15, 
FVC≥70% pred) 
29.5% 35.1% 0.345 
Cardiac output 4.5 l/min (1.4) 5.3 l/min (1.2) <0.0005 
Cardiac index 2.67 (0.77) 2.71 (0.78) 0.705 
Oxygen saturation 94.9% (4.2)  
n=320 
96.0% (2.9) 
n=76 
0.010
+
 
PVR 410.2 (393.3) 
n=333 
323.8 (241.9) 
n=74 
0.212
+
 
Pulmonary capillary 
wedge pressure 
10.1 (4.5) 
n=335 
12.3 (4.3) 
n=79 
0.0002 
 
* by Chi Squared,  + by Mann-Whitney test 
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We compared the baseline characteristics of patients with obesity (mean BMI 34.5) to patients 
without (mean BMI 23.6). 
Cardiac output, aortic pressures was normally distributed. However, right atrial pressure, 
systolic, diastolic and mean pulmonary artery pressures and pulmonary vascular resistance were 
not. 
We found that compared with non-obese patients, obese patients were three years younger and 
had slightly worse functional class. There was a trend towards a lower proportion of 
scleroderma in obese patients than in non-obese patients. 
On pulmonary function tests, the forced lung capacity was 200 millilitres less on average in 
obese patients than in non-obese patients, but there was no association with obstructive 
spirometry. There was no significant difference in smoking history. 
Heart rate and systolic blood pressure were similar, but there was a trend towards a 3mm higher 
diastolic pressure in obese patients. Right heart catheterisation showed slightly higher right 
atrial pressures in obese patients, and almost twice the incidence of post-capillary pulmonary 
hypertension (15% compared to 8% in this cohort). Pulmonary capillary wedge pressures were 2 
mmHg higher in obese patients on average. Cardiac output was slightly higher but cardiac index 
was similar. Oxygen saturation was slightly higher in obese patients. 
Amongst 123 patients with pulmonary arterial hypertension (precapillary pulmonary 
hypertension and forced vital capacity>70%), mean pulmonary artery pressure was 38.4 mmHg 
and  mean pulmonary vascular resistance was 557 dynes.s.cm
-5
. There was no significant 
difference between obese and non-obese patients in mean pulmonary artery pressure (p=0.68), 
right atrial pressure (p=0.81) or trans-pulmonary gradient (p=0.91). Cardiac output was higher 
in obese patients (5.3 vs 4.4 litres/minute, p=0.002) and there was a trend to lower pulmonary 
vascular resistance in obese patients (460 vs 584 dynes.s.cm
-5
, p=0.10). 
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Outcomes 
5 year survival data was analysed. In the cohort as a whole median survival was 71.6 months. 
There was no difference in survival between obese and non-obese patients (p=0.267).  
Figure 2. Kaplan-Meier survival curve in obese and non-obese patients 
Amongst patients with pulmonary hypertension (n=210) distribution of weights in patients was 
as follows: 12 patients were underweight (5.7%), 81 patients were of normal weight (38.4), 72 
were overweight (34.1%), 31 were class I obese (14.7%), 10 were class II obese (4.7%) and 5 
were class III obese (2.4%). The mean BMI in patients with pulmonary hypertension was higher 
than in patients without (26.4 vs 24.9, p=0.007). 
There was better outcome in obese patients (p=0.017 by log-rank). 3 year survival was 51.9% 
(95% CI 42.4,61.0) in non-obese patients but 71.3% (95% CI 52.4,83.8) in obese patients. On 
cox proportional hazards analysis, obesity was associated with a hazard ratio of 0.47 (p=0.020, 
95% CI 0.25,0.89). This difference persists after adjustment for age and gender. After 
adjustment for mean pulmonary artery pressure and cardiac output hazard ratio for obesity is 
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0.58, p=0.010. With adjustment for pulmonary capillary wedge pressure, the hazard ratio for 
obesity is 0.61, p=0.09. 
If the analysis is restricted to patients with pulmonary arterial hypertension (mPAP ≥ 25, PCWP 
≤ 15, FVC > 70% predicted) there is still a trend to better survival (n=123, hazard ratio 0.44, 
p=0.12, 95% CI 0.16, 1.24). 
The improved survival in obese patients with pulmonary hypertension compared to non-obese 
patients holds true even when patients who are underweight (BMI<18.5) or class III obese 
(BMI>40) are excluded from the analysis. Survival is better in patients with class I or class II 
obesity than in patients who are of normal weight or overweight (hazard ratio 0.47, p=0.025, 
95% CI 0.24,0.91). 
Compared to patients with class I obesity (BMI 30.0-34.9), underweight patients’ hazard ratio 
for mortality is 2.29 (p=0.179, 95% CI 0.68,7.69); patients of normal weight have a hazard ratio 
for mortality of 2.37 (p=0.026, 95% CI 1.11,5.08); patients with class II obesity (BMI 35.0-
39.9) have a hazard ratio of 1.13 (p=0.878, 95% CI 0.24,5.38) and those with class III obesity 
(BMI ≥40.0) have a hazard ratio of 1.16 (p=0.888, 95% CI 0.14,9.34). 
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Figure 3. Kaplan-Meier survival curve for patients with pulmonary arterial hypertension 
Among patients without pulmonary hypertension, there was no difference in survival between 
obese and non-obese patients (p=0.52). 
Discussion 
In our cohort of 417 patients with connective tissue disease, 19% were obese. Obese patients 
were on average 3 years younger than non-obese patients. They reported slightly more 
functional limitation, and the forced lung capacity was about 200ml smaller than non-obese 
patients. There was no association between obesity and smoking or systemic hypertension in our 
patients. 
Right heart catheterisation revealed some subtle changes associated with obesity. These 
included higher right atrial pressure (by 0.7 mmHg), slightly higher systolic and diastolic 
pulmonary artery pressures (by about 1.5 mm Hg) and higher average pulmonary capillary 
wedge pressure (by 2.2 mmHg). Cardiac output was higher by 0.8 litres/minute although cardiac 
index was similar in the two groups. Consequently post-capillary pulmonary hypertension was 
more frequently diagnosed amongst obese patients.  
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The higher wedge pressures in patients with obesity may reflect changes in left ventricular 
function related to obesity. Obesity is associated with subclinical left ventricular impairment of 
diastolic, and perhaps also systolic dysfunction.
32
 Furthermore, cardiac catheterisations 
performed in 10 asymptomatic obese volunteers showed raised wedge pressure and pulmonary 
artery pressures.
33
 However, determining the zero position in the body is more difficult in obese 
patients and this may partly explain the higher values. 
Consequently, post-capillary pulmonary hypertension was diagnosed in 15% of obese patients 
compared to 8% of non-obese patients. There was no significant difference in the incidence of 
pre-capillary pulmonary hypertension or pulmonary arterial hypertension using forced vital 
capacity>70% predicted to exclude significant lung disease. 
Our finding that there is no association between obesity and the prevalence of pulmonary 
arterial hypertension is in agreement with previous studies. A retrospective review of 401 
patients in the pulmonary hypertension (PH) database of Mayo Clinic in Florida found no 
correlation between BMI and diagnosis of PH when these patients were compared with controls 
(n=578).
34
 Burger and colleagues compared the distribution of body mass index in patients with 
pulmonary arterial hypertension from the REVEAL registry with age- and sex-matched controls 
in the National Health and Nutrition Examination Survey database. They found no difference in 
mean BMI overall. There was a higher proportion at either end of the weight spectrum which 
was attributable to the characteristics of specific subgroups: idiopathic pulmonary arterial 
hypertension and drugs and toxins associated pulmonary arterial hypertension subgroups had a 
higher percentage of obese patients compared with controls, whereas congenital heart disease 
and connective tissue disease associated pulmonary arterial hypertension subgroups had a 
higher percentage of underweight patients.
35
 
Our finding that obese patients with pulmonary hypertension had half the mortality of non-
obese patients is intriguing. To our knowledge, this has not been reported before. There have 
been reports of obesity as a protective factor in left heart failure. Among the 7599 patients in the 
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Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) 
program, patients with BMI<30 kg/m
2
 had higher mortality than patients with BMI>30 kg/m
2
.
36
 
This has been shown in other groups of patients with systolic heart failure, and has been called 
the ‘obesity paradox’. 37 , 38 , 39  It has been suggested that the adaptive morphological and 
functional cardiac changes in obesity may be protective, or that the adipose tissue itself, 
especially perivascular and epicardial fat, may be metabolically active and perhaps protective.
40
 
It has previously been suggested that this may be due to higher mortality in cachexic patients 
due to severe cardiac or non-cardiac disease in the non-obese group. However, we have shown a 
clear mortality benefit even when underweight patients were excluded from the analysis. 
It is possible that the higher capillary wedge pressures in patients with obesity reflect a greater 
incidence of post-capillary pulmonary hypertension even in patients with pulmonary capillary 
wedge pressure ≤ 15mmHg. We cannot exclude technical issues such as difficulty in deciding 
on the zero point which may tend to overestimation of pressures in larger patients. 
It is not clear whether the relationship between weight and pulmonary haemodynamics is 
different in patients with connective tissue disease. The REVEAL registry found that while 
patients with idiopathic pulmonary arterial hypertension have a higher BMI than the control 
group (29.1 vs 28.1, p<0.001), those with connective tissue disease associated pulmonary 
arterial hypertension have a lower BMI than controls (27.6 vs 28.7, p<0.001). Whether these 
small differences are due to comorbidities in connective tissue disease such as gastrointestinal 
involvement is unknown. 
Strengths of the study include the large cohort of connective tissue disease patients, the 
thorough investigation with pulmonary function tests and right heart catheterization and 
complete survival data. Our study has important limitations. Principally, that it is retrospective 
and there are incomplete data, especially pulmonary function tests. This finding would need to 
be replicated in a larger prospective cohort. 
79 
 
In summary, in patients with connective tissue disease obesity is associated with changes in 
pulmonary function tests and pulmonary haemodynamics. Obese patients are not more likely to 
be diagnosed with pulmonary arterial hypertension, but post-capillary pulmonary hypertension 
appears to be more prevalent. Obese patients with pulmonary hypertension have longer survival 
overall than non-obese patients, and a trend is seen to longer survival even when patients with 
lung disease or post-capillary pulmonary hypertension are excluded. The underlying reasons for 
this are not clear, and further prospective studies would be helpful in clarifying the role of 
obesity in the diagnosis and prognosis of pulmonary hypertension.  
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Chapter 5. Diagnosis and prognosis 
of pulmonary arterial hypertension 
in systemic lupus erythematosus and 
systemic sclerosis 
Benjamin Schreiber, Christopher Valerio, Clive Handler, David D’Cruz, Voon Ong, Gregory 
Keir, Athol Wells, Christopher Denton, Gerry Coghlan 
Oral presentation at Annual Scientific Meeting of the British Society of Rheumatology, 
Brighton, April 201 
Winner of Young Investigator Award 
Abstract 
Background 
PAH is less commonly associated with SLE than with SSc. Previous work has suggested that 
survival is better in SLE-PAH but it is not clear if this is because the disease is milder or there is 
a better response to therapy. 
Methods 
Single centre retrospective analysis of diagnostic right heart catheterisations performed in 
patients with SSc or SLE. We have analysed baseline parameters, response to treatment at 
follow up right heart catheter and survival. PAH was defined as mPAP≥25 mmHg, PCWP≤15 
mmHg, PVR ≥3 WU and FVC predicted (where available) ≥70%. 
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Results 
Patients with SLE-PAH are younger (n=21, mean 43.9 yrs) than patients with SSc-PAH (n=309, 
mean 60.7 yrs, p<0.00005 for comparison). Both patient groups were predominantly female 
(95.5% in SLE-PAH, 84.5% in SSc-PAH, p=0.16). 
Patients with SLE-PAH had higher mean mPAP than patients with SSc-PAH (47.0 and 41.0 
mmHg respectively, p=0.03 for comparison). PVR was similar (means of 780 and 689 
respectively, p=0.31). NT-pro-BNP values were also similar (SLE-PAH: n=9, mean 220 pmol/l. 
SSC-PAH: n=117, mean 248, p=0.84 for comparison). 
Pulmonary function tests showed a lower FVC % predicted in SLE-PAH (n=8, mean 81.4%) 
compared to SSc-PAH (n=157, mean 94.7%, p=0.03 for comparison). Nonetheless DLCO % 
predicted was lower in the SSc-PAH patients (SLE-PH: n=8, mean 52.7%. SSc-PH: n=139, 
mean 38.6%, p=0.0012 for comparison). WHO Functional class was similar in the two groups 
(mean 3.0 in SLE-PAH vs 3.1 in SSc-PAH, p=0.93). Six minute walking distance was on 
average 54 metres further in the SLE-PAH group (SLE-PAH: n=17, mean 301. SSc-PAH: 
n=178, mean 247, p=0.08 for comparison) 
However, survival is clearly better in SLE-PAH compared to SSC-PAH (log-rank test p=0.02). 
Median survival is 39.9 months in the SSc-PAH group (95% CI 30.9-45.2). Median survival 
was not reached in the SLE-PAH cohort, but the 95% confidence interval for the median 
survival starts at 76.8 months. 1 year survival is 81.4% (58-93) in SLE-PAH compared to 79.5% 
(74-84) in SSc-PAH.  5 year survival is 76% (95% CI 51-89) in the SLE-PAH cohort and 32.8% 
in the SSc-PAH cohort (95% CI 26-40). 
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 SLE-PAH (n=22) SSc-PAH (n=309) 
1 year 81.4% (58-93) 79.5% (74-84) 
3 year 76% (51-89) 52.7% (46-59) 
5 year 76% (51-89) 32.8% (26-40) 
Follow up catheterisation showed significantly more improvement in mPAP (-5.7 vs =0.6, 
p=0.01) and in PVR (-228 vs -38, p=0.006). A larger proportion showed any improvement in 
PVR in the SLE-PAH cohort (88% vs 62%, p=0.03). 
Cox proportional hazards analysis shows that underlying diagnosis (SLE vs SSc) is not a 
significant predictor of mortality after adjustment for age, baseline haemodynamics, and DLCO. 
Conclusion 
Compared to patients with SSc-PAH, patients with SLE-PAH are younger and have higher 
DLco % predicted. Intial pulmonary artery pressures are higher but haemodynamic responses to 
therapy in SLE-PAH are of greater magnitude and seen more frequently. These differences may 
account for the markedly better survival in patients with SLE-PAH. 
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Introduction 
Sir William Osler was the first to recognize that SLE may be associated with pulmonary 
complications.
41
 A post-mortem study of 90 patients with SLE associated pulmonary 
involvement included 4 patients with PH. Each of these patients had plexiform lesions (figure 
1).
42
 A number of the studies have used an unsatisfactory echocardiographic definition of 
pulmonary hypertension (e.g. Echo derived right ventricular systolic pressure greater than 
30mmHg).
43,44
 
Figure 1. Image of lung specimen from post-mortem study showing plexiform arteriopathy with organizing 
thrombosis in a patient with systemic lupus erythematosus. 
 
Source: Reference 42. 
Why should SLE be different? 
There are several possible causes of pulmonary hypertension in SLE, including recurrent 
thromboemboli, particularly in patients with antiphospholipid antibodies, pulmonary vasculitis, 
interstitial lung disease, left ventricular disease as well as pulmonary arterial hypertension 
similar to idiopathic PAH. There is some evidence that endothelin levels are elevated in patients 
with SLE and this may contribute to PAH.
45
 
Pulmonary hypertension in SLE is associated with active disease and with many other major 
organ complications. Patients with SLE and suspected PAH require investigations to exclude 
interstitial lung disease and pulmonary thromboembolic disease. Thromboembolic disease is 
certainly more common in patients with SLE and is a common finding at post-mortem,
46
 and the 
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presence of lupus anticoagulant or antiphospholipid antibodies is associated with a more than 4 
fold increase in the risk of chronic thromboembolic pulmonary hypertension.
47
 
There may be an important role for immunosuppression with cyclophosphamide and 
prednisolone in the treatment of PAH associated with SLE and MCTD. A small Mexican 
randomised open label study comparing cyclophosphamide to enalapril found a treatment 
benefit in terms of haemodynamic improvement and functional class improvement.
48
 A small 
French retrospective case series suggested that half of patients with SLE or MCTD and PAH 
respond to immunosuppression with steroids and monthly intravenous cyclophosphamide, 
especially those with functional class I or II.
49,50
 
Only a few patients with SLE-PAH have been included in the clinical trials of advanced 
therapies for pulmonary hypertension, although Bosentan was found to be helpful in a small 
case series.
51
 However, guidelines suggest patients with CTD-PAH should be treated in the 
same way as IPAH.
14
 
Data from baseline characteristics of the REVEAL cohort has recently been published.
52
 All 
newly and previously diagnosed patients with World Health Organization (WHO) group 1 PAH 
meeting RHC criteria at 54 US centers were consecutively enrolled. The inclusion criteria are 
mPAP > 25 mmHg or >30 mmHg with exercise, PCWP <18 mmHg and pulmonary vascular 
resistance of > 240 dynes.s.cm
-5
. For this study, patients with PCWP >15 were excluded, as 
were those with severe lung fibrosis on HRCT or with moderate lung fibrosis on HRCT and 
total lung capacity < 60% predicted. They found several differences between IPAH and CTD-
PAH patients. CTD-PAH patients were older, more frequently female and less obese. They had 
lower pulmonary artery pressures and higher cardiac outputs, lower six minute walking 
distances and higher NT-pro-BNP levels. They more frequently had mild ILD on HRCT and 
had lower DLco % predicted. One year survival was lower in CTD-PAH patients (86% vs 93%, 
p<0.0001). 
85 
 
Among patients with CTD-PAH and a defined CTD diagnosis, 399 had SSc, 110 had SLE, 52 
had MCTD and 28 had RA. Comparing SSc-PAH to SLE-PAH, age was different (61.8 ± 11.1 
years vs 45.5 ± 11.9 respectively, p<0.0001). There was a clear difference in race (The majority 
of patients with SSc-APAH were white (84%); in contrast, only 37% of patients with lupus 
were white, 32% were African American, 18% were Hispanic, and 13% were of another racial 
background). Raynaud’s phenomenon and renal insufficiency were more common in SSc-PAH 
patients. 
Treatments differed, with more endothelin receptor antagonists used in SSc-PAH than SLE-
PAH, and more immune suppressants in SLE-PAH than in SSc-PAH. At 1 year from the time of 
enrollment, 82% of the patients with SSc-PAH were alive, compared with 94% of the patients 
with SLE-PAH (p<0.0009). 
Results from the reveal registry: comparison of pulmonary arterial hypertension associated with systemic 
sclerosis and systemic lupus erythematosus 
 SSc associated PAH SLE associated 
PAH 
P value 
FC III/IV 74.8 69.8 Not sig. 
Mean PA pressure 44.6 46.6 Not sig. 
Pulmonary Vascular 
Resistance 
9.6 10.7 0.056 
6 min walk distance 288 324 0.12 
NTproBNP (pg/ml) 2893 740 0.01 
DLCO % predicted 41.2 53.3 <0.0001 
Source: Reference Error! Bookmark not defined.. 
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The prognosis of patients with SLE-PAH appears to be intermediate between idiopathic PAH 
and SSc associated PAH. In the UK national pulmonary hypertension data, 1 and 3 year survival 
in the 28 patients with SLE-PAH were 78% and 74% respectively. Of patients with SLE 75% 
were treated with advanced
 
therapy whereas 86% received immunosuppression.
53
 This study 
also found that although haemodynamics were similar in SLE and SSc, survival was better in 
SLE. 
PAH is less commonly associated with SLE than with SSc. Previous work has suggested that 
survival is better in SLE-PAH but it is not clear if this is because the disease is milder or there is 
a better response to therapy. 
Methods 
Single centre retrospective analysis of diagnostic right heart catheterisations performed in 
patients with SSc or SLE. We have analysed baseline parameters, response to treatment at 
follow up right heart catheter and survival. PAH was defined as mPAP≥25 mmHg, PCWP≤15 
mmHg, PVR ≥3 WU and FVC predicted (where available) ≥70%. 
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Results 
Table 1. Baseline characteristics in patients with SLE-PAH and SSc-PAH. 
 SLE-PAH 
n=21 
SSc-PAH 
n=234 
p value 
Age 46.2 60.3 <0.00005 
Male 9.5% 15.8% 0.45 
mPAP 45.9 40.5 0.08 
PVR 747 659 
(n=233) 
0.43 
NTproBNP 220 
(n=9) 
248 
(n=117) 
0.84 
FVC % predicted 82.9% (n=7) 96.3% (n=103) 0.036 
DLCO % predicted 53.1% 
(n=7) 
41.6% (n=108) 0.02 
Functional Class 3.0 3.0 
(n=231) 
0.56 
Six minute walking 
distance 
309 
(n=17) 
265 (n=132) 0.16 
 
Patients with SLE-PAH are younger (n=21, mean 43.9 yrs) than patients with SSc-PAH (n=309, 
mean 60.7 yrs, p<0.00005 for comparison). Both patient groups were predominantly female 
(95.5% in SLE-PAH, 84.5% in SSc-PAH, p=0.16). 
Patients with SLE-PAH had higher mean mPAP than patients with SSc-PAH (47.0 and 41.0 
mmHg respectively, p=0.03 for comparison). PVR was similar (means of 780 and 689 
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respectively, p=0.31). NT-pro-BNP values were also similar (SLE-PAH: n=9, mean 220 pmol/l. 
SSC-PAH: n=117, mean 248, p=0.84 for comparison). 
Pulmonary function tests showed a lower FVC % predicted in SLE-PAH (n=8, mean 81.4%) 
compared to SSc-PAH (n=157, mean 94.7%, p=0.03 for comparison). Nonetheless DLCO % 
predicted was lower in the SSc-PAH patients (SLE-PH: n=8, mean 52.7%. SSc-PH: n=139, 
mean 38.6%, p=0.0012 for comparison). 
WHO Functional class was similar in the two groups (mean 3.0 in SLE-PAH vs 3.1 in SSc-
PAH, p=0.93). 
Six minute walking distance was on average 54 metres further in the SLE-PAH group (SLE-
PAH: n=17, mean 301. SSc-PAH: n=178, mean 247, p=0.08 for comparison) 
Figure 1. Kaplan-Meier survival in Patients with SSc-PAH and SLE-PAH 
 
Survival in the two cohorts from the time of the diagnostic right heart catheter is shown in 
figure 1. Median survival was 45.2 months in SSc-PAH (95% CI 39-55). Median survival was 
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not reached in patients with SLE-PAH but 95% CI start at 76.8 months. Cox proportional 
hazards analysis shows that the diagnosis of SSc-PAH is associated with an odds ratio of 3.0 
(95% CI 1.2,7.3, p=0.017) for mortality. On multivariable cox proportional hazards analysis, 
age (p<0.0005), functional class (p=0.003), gender (p=0.01) and baseline pulmonary vascular 
resistance (PVR, p<0.0005) are each independently associated with survival. There was a trend 
towards worse survival in patients with SSc-PAH even after adjustment for these factors (OR 
2.3, CI 0.9,5.7. p=0.08). 
However, median survival is better in SLE-PAH compared to SSC-PAH (log-rank test p=0.02). 
Median survival is 39.9 months in the SSc-PAH group (95% CI 30.9-45.2). Median survival 
was not reached in the SLE-PAH cohort, but the 95% confidence interval for the median 
survival starts at 76.8 months. 
1 year survival is 81.4% (58-93) in SLE-PAH compared to 79.5% (74-84) in SSc-PAH.  5 year 
survival is 76% (95% CI 51-89) in the SLE-PAH cohort and 32.8% in the SSc-PAH cohort 
(95% CI 26-40). 
 SLE-PAH (n=22) SSc-PAH (n=309) 
1 year 81.4% (58-93) 79.5% (74-84) 
3 year 76% (51-89) 52.7% (46-59) 
5 year 76% (51-89) 32.8% (26-40) 
 
Follow up catheterisation showed significantly more improvement in mPAP (-5.7 vs =0.6, 
p=0.01) and in PVR (-228 vs -38, p=0.006). A larger proportion showed any improvement in 
PVR in the SLE-PAH cohort (88% vs 62%, p=0.03). 
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Cox proportional hazards analysis shows that underlying diagnosis (SLE vs SSc) is not 
independently associated with survival after adjustment for age, baseline haemodynamics, and 
DLCO. 
In order to understand what else contributes to the difference in outcome in these two patient 
groups, we assessed the haemodynamics at follow up RHC. After initiation on pulmonary 
hypertension specific therapies with PDE5 inhibitors, ERAs or prostacyclins, RHC was 
repeated, usually at 3-6 months. 
Repeat right heart catheterisation was performed in 17 of 21 patients with SLE-PAH and 166 of 
234 patients with SSc-PAH. Despite similar baseline values, PVR was improved in 81% of 
patients with SLE-PAH compared to 55% of patients with SSc-PAH (p=0.045). The average 
PVR change was an improvement of 188 dynes.s.cm
-5
 in patients with SLE-PAH but an 
improvement of only 24 dynes.s.cm
-5
 in patients with SSc-PAH [Table 2]. 
Table 2. Change in Haemodynamics after PAH specific therapies 
 
  
SLE-PAH 
n=21 
SSc-PAH 
n=234 
p value 
Change in PVR 
(dynes.s.cm
-5
) 
-188 
(n=16) 
-24 
(n=161) 
0.028 
Change in mPAP 
(mm Hg) 
-4.6 
(n=17) 
+0.4 
(n=166) 
0.045 
Any PVR 
improvement 
81.3% 55.3% 0.045 
Thus there is a clear difference in change in pulmonary vascular resistance in patients with SLE-
PAH and SSc-PAH [Table 2]. However, the relative changes are small. The mean change is -
5.5% in those with SLE-PAH (95% CI -46,35.0) and +3.3% in those with SSc-PAH (95% CI -
4.1,10.8). 
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Cox proportional hazards analysis shows that absolute change in PVR is independently 
associated with mortality (OR 1.15 per 1 unit increase in PVR in wood units, 95% CI 1.08,1.23, 
p<0.0005), even after adjustment for age (OR 1.08 per year increase, 95% CI 1.05,1.11, 
p<0.0005), gender (2.21 for males, 95% CI 1.15,4.23, p=0.018), functional class (not 
significant, 0.87 so dropped) and baseline pulmonary vascular resistance (OR 1.22 per wood 
unit, 95% CI 1.16,1.29, p<0.0005). 
Those patients with an improvement in PVR have a clearly better outcome than those who do 
not, with 42% less mortality (Odds ratio 0.58, 95% CI 0.36,0.92, p=0.02). Median survival in 
responders is 54.4 months (95% CI 33.9,71.6) and in non-responders it is 96.5 months (95% CI 
53.6 - ). Patients with any PVR response survive longer than those without a response (p=0.04 
by log-rank). 
Nonetheless, even after adjustment for age, gender, baseline PVR and change in PVR, patients 
with SSc-PAH tend to worse survival than those with SLE-PAH (odds ratio 4.2, 95% CI 
0.98,18.4, p=0.054), suggesting that there may be other factors at play to explain the worse 
survival in SSc-PAH. 
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Table 3. 
Variable Odds ratio CI P 
PVR better 0.58 0.36,0.92 0.02 
Age 1.08 1.05,1.11 <0.0005 
Gender 2.3 1.20,4.42 0.013 
Functional Class 0.96 0.67,1.36 0.81 
Discussion 
We have shown that patients with SLE-PAH are different to patients with SSc-PAH. They are 
younger, less frequently male and tend to have slightly higher mean pulmonary artery pressures. 
Furthermore, patients with SLE-PAH show a more frequent and marked improvement in PVR 
after treatment with PH specific therapies. We have also shown that improvement in PVR at 
follow up right heart catheterisation is associated with better survival. Finally, we have shown 
that the difference in survival between the two cohorts is not entirely explained by these 
differences. 
SLE-PAH may well be a different disease to SSc-PAH. Patients with SLE-PAH may have 
different pathophysiology, with more frequent pulmonary vasculitis and pulmonary 
thromboembolic disease in patients with SLE. The derangements in the immune system are 
different in patients with SLE and SSc, and this may impact on response to treatment. 
Limitations of our study are its retrospective nature, leading to some incomplete data and 
limiting our ability to infer whether the improvements in PVR were due to treatment or to 
natural history of the disease. 
Our data suggests that change in haemodynamics at 3-6 months is associated with survival, with 
about 42% less mortality in those who respond than in those who do not. This may have 
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implications for clinical practice as it demonstrates that even small improvements in PVR 
predict improved survival. Change in PVR may therefore be an important indicator that 
treatment is working and may be another useful surrogate measure of clinical improvement in 
clinical trials. 
Conclusion 
Compared to patients with SSc-PAH, patients with SLE-PAH are younger and have more 
preserved DLco. Initial pulmonary artery pressures are higher but haemodynamic responses to 
therapy in SLE-PAH are more common and of greater magnitude in SLE-PAH than in SSc-
PAH. These differences may account for the markedly better survival in patients with SLE-
PAH. 
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Chapter 6. Prevalence and 
significance of CT findings suggestive 
of pulmonary veno-occlusive disease 
in systemic sclerosis 
B. E. Schreiber, G. Keir, D. Dobarro, C. Handler, S. Nihtyanova, J. Suntharaligam, N. 
Sverzelatti, G. Robinson, D. Hansell, A. U. Wells, C. P. Denton, J. G. Coghlan. Poster Abstract 
presentation, ACR, Washington, November 2012. 
Abstract 
Background 
Recent reviews have suggested a high prevalence of pulmonary venoocclusive disease (PVOD) 
amongst patients with systemic sclerosis associated pulmonary hypertension. We tested this 
hypothesis on a large series of patients. 
 Methods 
A retrospective study of 117 patients with systemic sclerosis who underwent CT of the chest 
within six months of a diagnostic right heart catheterisation. The CTs were blindly scored by 
two independent radiologists for extent of interstitial lung disease, vessel size and features of 
PVOD. Each lung quadrant was scored separately for interlobular septal thickening (IST) with 
score 0-5 and centrilobular nodules (CLN), score 0-3. Survival data was collected on all 
patients. 
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Results 
Mean age was 57.8 (range 22-85). 78% were female. 84 patients had LcSSc, 32 had DcSSc and 
1 had MCTD. CT scans were performed a mean of 2.7 months from the RHC. 
There was limited or no ILD extent (<20%) in 46 patients (43%), indeterminate in 28% and 
extensive (>20%) in 30%. On right heart catheterisation 53% had precapillary PH while 47% 
did not.  
 Of 117 scans, 22 scans could not be fully reported by both radiologists. Of the remaining 95 
patients, 49 had PAH and 46 did not. Of those with PH, 18 had <20% ILD, 18 had ~20% ILD 
and 13 had >20% ILD. There was a weak trend towards worse survival with more lung disease 
(HR 1.5, 95% CI 0.89,2.52, p=0.13). 
 Mean IST score was 1 (on a scale of 0-4) and mean CLN score was 0.63 (scale of 0-2). IST was 
not associated with extent of ILD (p=0.19 by chi-square), and nor was CLN (p=0.74, by chi-
square).  
 IST did not correlate with PVR (R2=2%) whereas CLN did correlate with PVR (R2=15.7%). 
 On Cox proportional hazards analysis, PVR was a strong predictor of death (p=0.001). 
Increasing IST was associated with worse survival on univariate analysis (p=0.038), however 
this finding is lost (p=0.11) after adjusment for age. 
 Increasing CLN is strongly associated with higher mortality (p=0.013) even after adjustment 
for age, gender, extent of interstitial lung disease and mean pulmonary artery pressure 
(p=0.047). This is particularly so in patients without PH (p=0.004 on this multivariate analysis) 
rather than in patients with PH (where p=0.19 on multivariate analysis). However, not after 
adjustment for PVR (p=0.18). 
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Conclusion 
Interlobular septal thickening and centrilobular nodules are frequently seen in patients with 
systemic sclerosis and are each associated with worse survival. However, IST increases with 
age and CLN increases with worsening pulmonary vascular resistance. We have not found that 
they are independent predictors of worse outcome in systemic sclerosis. 
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Introduction 
Pulmonary veno-occlusive disease (PVOD) is a rare variant of pulmonary hypertension 
characterised histologically by involvement of the pulmonary venule and clinically by a 
progressive course with poor response to pulmonary vasodilators, which may indeed precipitate 
pulmonary oedema. PVOD is associated with changes on computed tomography of the chest, 
especially lymphadenopathy, septal lines and centriloblar ground glass opacities.
54
 
Small histopathological case series have suggested that pulmonary veno-occlusive disease may 
be more common in systemic sclerosis than in idiopathic pulmonary arterial hypertension.
55,56
 In 
a recently reported French series, a high prevalence of these radiological findings were seen in 
patients with systemic sclerosis associated pulmonary hypertension, and these were associated 
with a high prevalence of pulmonary oedema following treatment with pulmonary 
vasodilators.
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However, whether these radiological features are present in patients with systemic sclerosis 
without pulmonary hypertension has not been fully explored. We sought to explore the clinical 
associations of interlobular septal thickening and centrilobular nodules in patients with systemic 
sclerosis with or without pulmonary hypertension and interstitial lung disease. 
Patients and Methods 
A retrospective study of 95 patients with systemic sclerosis who underwent CT of the chest 
within six months of a diagnostic right heart catheterisation. The CTs were blindly scored by 
two independent radiologists for extent of interstitial lung disease, vessel size and features of 
PVOD. Each lung quadrant was scored separately for interlobular septal thickening (IST) with 
score 0-5 and centrilobular nodules (CLN), score 0-3. Survival data was collected on all 
patients. Survival was collected from the NHS national database. 
Analyses were performed using Stata 10.0. Scans were reported by two radiologists. For the 
purposes of these analyses, we determined that patients who were scored by both radiologists as 
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having extensive disease as extensive, those scored by both radiologists as limited and the rest 
as intermediate. 
Results 
Mean age was 59.2 (range 22-85). 80% were female. 69 patients (73%) had limited scleroderma 
while 26 (27%) had diffuse disease. CT scans were performed a mean of 2.6 months from the 
RHC (range 0-6 months). 
Parenchymal disease (>5%) was present in half of the patients (48 patients, 50.5%). 
Parenchymal disease was seen in similar proportions in limited (37 of 69 patients) and diffuse 
(11 of 26 patients) scleroderma (chi squared =0.33). 
In those with parenchymal lung disease the overall disease extent was scored as limited (<20%), 
indeterminate or extensive (>20%). The proportions were reported by each radiologist (kappa 
0.67). 42-61% had limited lung involvement, 5-6% had indeterminate and 29-46% had 
extensive lung involvement. Overall, 41 patients (43%) had no or <20% lung involvement, 29% 
had intermediate lung involvement and 25% had extensive lung involvement. This did not differ 
by disease subtype (χ2 p=0.25). 
All patients also underwent right heart catheterisaton. Mean pulmonary artery pressure was 28.2 
mmHg with no difference between those with interstitial lung disease (mean pressure 27.4 
mmHg) and those without (mean pressure 28.9 mmHg, p=0.52). 
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 Mild ILD 
0-20% 
(n=41) 
Moderate ILD 
Approx 20% 
(n=29) 
Severe ILD 
More than 20% 
(n=25) 
Age (years) 59.9 60.9 56.2 
Female (%) 78.0 82.8 80.0 
Limited subtype (%) 78.0 75.9 60.0 
Mean PA (mmHg) 26.5 33.2 25.1 
Wedge pres (mmHg) 11.1 10.8 8.3 
Precapillary PH 43.9% 65.5% 48% 
PVR (dynes.s.cm
-5
) 288 454 324 
5 year survival 72% (54-83) 71% (49-84) 44% (22-64) 
Table 1. Demographics, disease subtype, pulmonary haemodynamics and survival by ILD group 
Survival did not differ significantly among these groups.  
 Interlobular septal thickening (IST) 
IST scores are shown in Figure 1a. Agreement between radiologists was low (kappa 0.17-0.45). 
IST was strongly associated with age, but it was not associated with presence of PH or ILD 
(Table 2, Figure 1b). Mortality was higher in patients with IST (HR 2.12, 95% CI 1.12-4.01, 
p=0.02) but not after adjustment for age. 
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 No interlobular septal 
thickening 
n=60 
Interlobular septal 
thickening 
n=35 
P value 
Age  55.9 64.9 0.0004 
Gender  85% female 71% female 0.11 
Presence of ILD  53% 46% 0.48 
Presence of PH  51.7% 51.4% 0.98 
PCWP  10.2 mmHg 10.4 mmHg 0.88 
Table 2. Patient characteristics by presence of interlobular septal thickening 
 
 
Figure 1a and 1b. Distribution of interlobular septal thickening scores. Distribution of interlobular septal 
thickening score by age. 
Centrilobular nodules (CLN)  
CLN scores are shown in Figure 2a. Only 12% had CLN. Agreement between radiologists was 
poor (Kappa 0.16-0.49). 
CLN was not associated with age or presence of ILD (Table 3). However, it was associated 
with PH and correlated with PVR (R
2
=15.7%, Figure 2b).  
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Significant CLN is strongly associated with higher mortality (HR 3.19, 95% CI 1.34-7.64, 
p=0.009). This persists after adjustment for gender and extent of interstitial lung disease but not 
after adjustment for PVR.  
Of 22 patients with significant CLN or IST, 17 had PH and were treated with PDE5 (n=11), 
ERA (n=12), prostacyclins (n=7). None clinically had PVOD.  
 No CLN 
n=83  
CLN  
n=12  
P value  
Age  58.8  62.1  0.39  
Gender  79.5% female  83.3% female  0.76  
Presence of ILD  47%  75%  0.07  
Presence of PH  47%  83%  0.02  
PCWP  10.3  10.5  0.85  
Table 3. Patient characteristics by presence of centrilobular nodules. 
 
Figure 2a and 2b. Distribution of scores for centrilobular nodules and relationship between pulmonary 
vascular resistance and centrilobular nodule score. 
Discussion 
In this study we have shown that interlobular septal thickening and centrilobular nodules are 
common findings present in 37% and 12% of scans respectively. Agreement between two 
blinded independent radiologists was poor. 
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We found that interlobular septal thickening was associated with older age. We confirmed that 
IST is a negative prognostic factor but found that increasing age was an important confounder. 
Case notes review of the patients with significant IST and CLN found that although patients 
were treated with PDE5 inhibitors, ERA and prostacyclins, of 17 patients with PH and 
significant IST or CLN, none had PVOD clinically.  
There are several lines of evidence pointing to increased risk of pulmonary veno-occlusive 
disease in scleroderma. A Dutch study compared histology from lung tissue of 8 patients with 
scleroderma associated pulmonary arterial hypertension and 11 idiopathic pulmonary arterial 
hypertension patients. They found focal fibrosis of veins or venules and associated capillary 
congestion in 4 of the 8 scleroderma patients and in 3 of 11 patients with idiopathic PAH. Of the 
8 patients, they describe CT findings ‘associated with PVOD’ in 7, including ground glass in 6 
of 8 patients and septal lines in 3 of 8 patients.
55
 
In another histopathological study, Dorfmuller and colleagues compared lung samples from 8 
patients with connective tissue disease associated pulmonary arterial hypertension (5 
postmortem, 3 after lung transplantation) with 29 patients with pulmonary arterial hypertension 
due to other causes. They found significant obstructive pulmonary vascular lesions 
predominating in veins/preseptal venules in 6 (75%) of 8 patients with CTD associated 
pulmonary arterial hypertension but in only 5 (17.2%) of 29 non–connective tissue patients with 
pulmonary arterial hypertension.
56
 
In an important early French study of patients with pulmonary arterial hypertension who had 
undergone lung biopsies between 1991 and 2004, 24 patients with pulmonary veno-occlusive 
disease were compared to 24 patients with plexiform lesions but no veno-occlusive disease. 
These patients had pulmonary arterial hypertension which was idiopathic, familial, or associated 
with a history of anorexigen use. The CTs of 20 patients with biopsy-confirmed pulmonary 
veno-occlusive disease were compared to 13 patients with PAH by two blinded experienced 
radiologists. Septal lines and centrilobular ground glass opacities were more common in patients 
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with PVOD than with controls. Of the 24 patients, 16 were treated with specific therapies, and 8 
episodes of pulmonary oedema occurred in 7 patients. Patients with connective tissue diseases 
were excluded from this study.
54
 
A recent French series found a high prevalence of centrilobular ground-glass opacities in SSc-
PAH compared to SSc without PH (46.2% versus 10.7%), and of septal lines (88.5% versus 
7.1%).
57
 They found a correlation between these signs and pulmonary oedema after initiation of 
PH specific therapies. 
A recent review of the CT findings in PVOD highlights the non-specific nature of some of these 
features.
58
 We found that these CT signs were common in scleroderma patients and were 
adverse prognostic features. However, our analysis suggests that IST and CLN may reflect 
increasing age and worse PH respectively. Interlobular septal thickening and centrilobular 
nodules are not specific findings. They are common in scleroderma patients without pulmonary 
hypertension. They are indeed markers for poor prognosis but they may be reflecting the 
presence of known risk factors, namely older age and worse pulmonary hypertension 
respectively. In our patients they did not correlate with clinical features of pulmonary veno-
occlusive disease.  
Appendix: Proforma for CT chests 
Main pulmonary artery & Pericardium 
Main PA short axis diameter and adjacent ascending aorta (at the 
level of the PA bifurcation) 
   0= aorta > main PA,  1= main PA=aorta , 2= main PA > aorta 
 
Main PA short axis diameter 
(where the main PA is in continuity with the right main PA)  
 
Anterior superior pericardial recess  
   0= no fluid or thickening,  1= minimal thickening/fluid (<10mm),   
2= extensive thickening /fluid (>10mm) 
 
 
Lobar characteristics 
Right upper lobe 
RUL apical segmental artery short 
axis diameter 
 Left upper lobe 
LUL  apical segmental artery 
 short axis diameter 
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Artery:bronchus ratio 
(score 1-5) 
 
Interlobular septal thickening 
(score 1-5) 
   - central, peripheral or mixed 
 
Centrilobular nodules 
0= not visible, 1=visible, 2=profuse 
 
Mosaicism 
0= 0%, 1=1-25%, 2= 26-50% 
3= 51-75%, 4= 76-100% 
 
Predominant pattern 
Ground glass         Reticular           
Mixed 
 
  
Artery:bronchus ratio 
(score 1-5) 
 
Interlobular septal thickening 
(score 1-5) 
   - central, peripheral or mixed 
 
Centrilobular nodules 
0= not visible, 1=visible, 
2=profuse 
 
Mosaicism 
0= 0%, 1=1-25%, 2= 26-50% 
3= 51-75%, 4= 76-100% 
 
Predominant pattern 
Ground glass      Reticular       
Mixed 
 
  
  
  
  
Right Lower lobe 
RLL apical segmental artery 
 short axis diameter 
 
Artery:bronchus ratio 
(score 1-5) 
 
Interlobular septal thickening 
(score 1-5) 
   - central, peripheral or mixed 
 
Centrilobular nodules 
0= not visible, 1=visible, 2=profuse 
 
Mosaicism 
0= 0%, 1=1-25%,2= 26-50% 
3= 51-75%,4= 76-100% 
 
Predominant pattern 
Ground glass      Reticular        Mixed 
 
 Left Lower Lobe 
LLL  apical segmental artery 
 short axis diameter 
 
Artery:bronchus ratio 
(score 1-5) 
 
Interlobular septal thickening 
(score 1-5) 
   - central, peripheral or mixed 
 
Centrilobular nodules 
0= not visible, 1=visible, 
2=profuse 
 
Mosaicism 
0= 0%, 1=1-25%,2= 26-50% 
3= 51-75%,4= 76-100% 
 
Predominant pattern 
Ground glass       Reticular        
Mixed 
 
  
  
  
  
  
Overall Disease Extent 
 
Limited           Extensive         
Indeterminate 
(<20%)             (>20%) 
 
 
 
Detailed scoring instructions 
 
Window level : Settings of 1500 width and a level of -500 HU 
 (main PA, right and left main PA were assessed on mediastinal window settings of width 400, 
and level of 40 HU) 
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Main PA and adjacent ascending aorta 
Comparative sizes of the short axis diameter of the main PA and adjacent ascending AA on 
axial CT at the level of the bifurcation of the main PA, where the left and right main PAs are 
judged to be present in equal measure 
0= aorta larger than main PA 
1= main PA equal in size to aorta 
2= main PA definitely larger than the aorta 
 
Main PA short axis diameter 
Main PA short axis diameter was obtained on axial CT section where the main PA is in 
contiuity with the right main PA (in the cases where more than one CT section fulfilled the 
criteria, the largest short axis diameter was recorded. The reading was taken at a point 
equivalent to within 1 cm of the mid AP diameter of the adjacent ascending aorta 
 
Pericardium 
Abnormalities of the anterior superior pericardial recess between the ascending aorta and 
pulmonary trunk 
0= no fluid or thickening 
1= minimal thickening of, or fluid within, the anterior-superior pericardial recess (depth 
<10mm) 
2= extensive thickening of, or fluid within, the anterior pericardial recess (depth >10mm 
 
Artery:bronchus ratio 
ABR is visually estimated for the upper and lower lobe segmental pulmonary arteries and their 
accompanying bronchus.  
1= ratio of short axis diameter of artery to short axis outer diameter of bronchus less than 0.75 
2= ratio between 0.75 and ≤1.25 
3= ratio between 1.25 and <2 
4= ratio between 2 and ≤ 3 
5= ratio >3 
 
Interlobular septal thickening 
0= no visible interlobular septa 
1= <5 visible interlobular septa 
2= ≥5 visible interlobular septa over <50% of the pleural surface 
3= interlobular septa of >50% of the pleural surface 
4= profuse interlobular septa 
 
Mosaicism 
Extent of decreased attenuation attributable to vascular disease 
0= 0% 
1= 1-25% 
2= 26-50% 
3= 51-75% 
4= 76-100% 
 
Overall disease extent 
The extent of reticular change and ground glass change was evaluated from the origin of the 
great vessels to immediately above the right hemidiaphragm and scored as: 
Limited involvement: <20% 
Extensive involvement: >20% 
Indeterminate 
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Chapter 7. The Double Whammy: 
Survival in Systemic Sclerosis with 
Interstitial Lung Disease and 
Pulmonary Hypertension  
Schreiber BE et al, Oral Presentation at American Congress of Rheumatology Annual Meeting, 
Chicago 2011 
Abstract 
Background 
Predictors of survival in systemic sclerosis patients with concurrent interstitial lung disease and 
pulmonary hypertension are poorly understood. 
Methods 
Retrospective analysis of a large regional single centre cohort of patients with systemic sclerosis 
associated pulmonary hypertension. Inclusion criteria were a diagnosis of systemic sclerosis, 
precapillary pulmonary hypertension as defined by mean pulmonary artery pressure (mPAP) ≥ 
25 mmHg and pulmonary capillary wedge pressure (PCWP) ≤ 15 mmHg, and FVC < 70% 
predicted and presence of significant lung fibrosis on CT. 
Results 
76 patients were identified. Mean age was 54.9 years. 51 (67%) female. 34 (44.7%) were 
classified to diffuse subset. Mean haemodynamics were: mPAP 37.3, PVR 554.6 dynes.s.cm-5. 
Median survival was 34.3 months (95% CI 23.4-55.7). 
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The following variables did not predict survival on univariable analysis: age (p=0.09), gender 
(p=0.59), right atrial pressure (0.47). heart rate (0.36), cardiac output (0.29), cardiac index 
(0.76), mean pulmonary artery pressure (p=1.00), pulmonary vascular resistance (p=0.08), 
oxygen saturation (p=0.41), mixed venous saturation (p=0.23), systolic blood pressure (p=0.37), 
diastolic blood pressure (p=0.10), six minute walking distance (p=0.10, n=47), NTproBNP 
(p=0.98, n=27), FVC % predicted (p=0.72), anti-centromere antibody status (p=0.31), anti-
topoisomerase-1 antibody status (p=0.12). 
Significant variables on univariate analysis were functional class (p=0.007), Dlco % predicted 
(p=0.03), FVC/DLCO (p=0.006) and Kco % predicted (p<0.0005, n=76). On multiple variable 
Cox analysis with these four variables, Kco % predicted is the only significant predictor 
(p=0.017). 
Kco % predicted has tertiles at 54.2 and 69.6. Kco % predicted was grouped into tertiles: <55%, 
55-70%, >70%. The hazard ratio associated with dropping by one category is 2.4 (95% CI 1.5-
3.7). 
 
The survival differs in the three groups (p=0.0002 by log-rank). 1, 3 and 5 year survival by 
group is given below: 
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 1 yr survival 3 yr survival 5 yr survival 
Kco > 70% predicted 90.3% (67-98) 78.9% (53-92) 71.0% (43-87) 
Kco 55-70% predicted 84.4% (63-94) 53.4% (32-71) 36.0% (16-57) 
Kco < 55% predicted 80.4% (59-91) 18.5% (6-37) 9.2% (2-25) 
Conclusions 
Patients with systemic sclerosis, interstitial lung disease and pulmonary hypertension have a 
poor survival. We found that no demographic and haemodynamic variables predicted survival in 
this patient cohort. 
On multiple variable models the only significant independent predictor of survival was Kco % 
predicted, which is the calculated diffusion of carbon monoxide adjusted for alveolar volume. 
KCO may reflect the extent of impairment of parenchymal dysfunction by combining both 
interstitial and vascular components of the disease process. 
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Introduction 
Patients with systemic sclerosis often have both interstitial lung disease (30-40% lifetime risk) 
and pulmonary hypertension (10-15% lifetime risk). The concept of “disproportionate PH” 
remains controversial. Prognostic factors are not well understood in this cohort. 
Previous work from the UK National Audit has compared 259 patients with SSc-PAH to 56 
patients with SSc-ILD-PH. Survival was worse with respiratory disease (p=0.02).
53
 
 
Source: Reference 53. 
A study from John Hopkins hospital in Baltimore compared 39 patients with SSc-PAH to 20 
patients with SSc-ILD-PH. They found worse survival in patients with lung disease. Survival 
was 87% at 1 year , 79% at 2 years and 64 % at 3 years in SSc-PAH. By comparison it was 82% 
at 1 year, 46% at 2 years and 39% at 3 years in SSc-ILD-PH.
59
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Source: Reference 59. 
 
Source: Reference 59. 
In this study we compared survival of patients with SSc, pulmonary hypertension and interstitial 
lung disease (SSc-PH-ILD) as defined by pulmonary function tests (PFTs) to those with 
preserved lung volumes (PAH). We analysed the variables associated with outcome in patients 
with SSc and PH-ILD. 
Patients and Methods  
Patients 
We analysed a prospectively collected database of all diagnostic right heart catheter (RHC) 
studies performed on SSc patients in a national PH referral centre from 1995-2010. Inclusion 
criteria were a diagnosis of SSc (including SSc overlap syndromes) and precapillary PH (mean 
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pulmonary artery pressure (mPAP) ≥ 25 mmHg and pulmonary capillary wedge pressure 
(PCWP) ≤ 15 mmHg). Patients for whom contemporary PFTs (FVC % predicted, DLCO % 
predicted and KCO % predicted within six months of the RHC) were not available were excluded 
from the analysis. 
Of 844 patients who underwent RHC, 78 patients had postcapillary PH and 437 had precapillary 
PH. Of these 437 patients, complete PFTs were available in 227 patients who formed the study 
group. An FVC threshold of below 70% predicted was taken as significant lung disease. Of 
these 227 patients, 76 had FVC < 70% predicted (SSc-PH-ILD) and 151 had FVC ≥ 70 % 
predicted (SSc-PAH). These two patient groups were compared, and the association between 
baseline data and survival in patients with SSc-PH-ILD were assessed. 
Investigations were performed as part of routine clinical care. Catheterization was performed in 
scleroderma patients with clinical suspicion of PH. In general, RHC was considered in any 
patient with tricuspid jet velocity >3.2 metres/second, in patients with tricuspid jet velocity 
between 2.8 and 3.2 m/s if there was any clinical suspicion of PH and in patients with tricuspid 
jet velocity below 2.8 m/s if there was a strong clinical suspicion or unexplained progression of 
exertional dyspnea.  
Clinical Data 
Oxygen saturation measurements were taken at the time of the RHC. This was measured on 
room air at the finger if there was an excellent signal or by femoral arterial puncture and blood 
gas analysis. Patients taking supplementary oxygen had their oxygen stopped to establish 
baseline oxygen saturation. One patient could not be taken off supplementary oxygen and was 
excluded from the analysis. 
PFTs were performed at the Royal Free Hospital or the Royal Brompton Hospital. 
Data Analysis 
Analyses were performed using STATA
®
 software (STATA version 10.0 for Windows, Texas, 
USA). Data were expressed
 
as means (SD) or medians (range), depending on distribution.
 
Group 
112 
 
comparisons were made using Student's t test or chi-square test as appropriate.
  
A P value of less 
than 0.05 was considered significant. 
For survival analysis, univariate analyses were performed using Kaplan-Meier curves and log-
rank test for categorical variables and univariate Cox proportional hazard regression for 
continuous variables.  
Variables with p value under 0.2 were carried forward as potential variables for inclusion in the 
final model. Age and gender were also included. The least significant variables were then 
removed sequentially until only variables with strong statistical associations (p<0.05) were 
included. 
Results 
Study Population 
Within the study sample of 227 patients, patients were classified as PAH if FVC ≥ 70% 
predicted (n=151, mean FVC 94.2% predicted) and SSc-PH-ILD if FVC < 70% predicted 
(n=76, mean FVC 54.2 % predicted). The mean number of days between PFTs and RHC was 
51.3 (SD 51.1). Compared to the patients in the PAH group, patients in the SSc-PH-ILD group 
were younger, more frequently male and more commonly had diffuse subset scleroderma and 
anti-scleroderma 70 antibodies. The SSc-PH-ILD patients were more frequently in worse 
functional class. Haemodynamic measurements at RHC were similar in the two groups. 
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 SSc-PAH 
(FVC ≥ 70% 
n=151) 
SSc-PH-ILD 
(FVC < 70% 
n=76) 
p value 
Age 61.2 54.9 0.0001 
Gender 18.5% male 32.9% male 0.016* 
Ever smoker 55/103 22/53 0.14* 
LcSSc subset 128/147, 87.1% 39/73, 53.4% <0.0005* 
DcSSc subset 19/147, 12.9% 34/73, 46.6% <0.0005* 
Anti-Centromere 53.4% (n=131) 14.0% (n=57) <0.0005* 
Anti-Scl70 6.6% (n=121) 35.6% (n=59) <0.0005* 
Oxygen saturation 94.4% (n=146) 93.4% (n=74) 0.45* 
DLco % predicted 40.9 % 31.1 % <0.0005 
Kco % predicted 53.0 % 61.5 % 0.0003 
Heart rate 82 84 0.29 
Mean RA pressure 7.4 7.7 0.65 
Mean PA pressure 38.7 37.3 0.36 
Mean wedge pressure 9.6 9.3 0.48 
PVR (dynes.s.cm
-5
) 572.4 554.6 0.73 
Functional class 2.9 (n=142) 3.3 (n=73) <0.0005* 
Six minute walk 248 m (n=101) 220 m (n=37) 0.23 
NTproBNP 190 pmol/l (n=66) 136 pmol/l (n=17) 0.44 
* χ2 square test 
Comparison of Survival 
Median survival across both groups was 45.1 months (95% CI for mean 36.6-58.5). Median 
survival was 52.6 (95% CI  40.8-71.6) in Group 1 and 34.3 (23.4-55.7) in Group 3. After 
adjustment for age and gender, the diagnostic group was not significantly associated with 
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outcome (HR 1.30, p=0.20, CI 0.87-1.96). 1,2 and 3 year survival were 88%, 73% and 64% in 
PAH patients compared to 85%, 61% and 48% in SSc-PH-ILD patients. Overall survival in the 
first three years was better in the PAH patient group (p=0.03 by log-rank), but the difference 
was not significant over the first 5 years as a whole (p=0.10 by log rank) or over the first ten 
years (p=0.20 by log rank). 
 
Survival in SSc-PH-ILD: Univariate Model 
We studied the 76 patients with SSc-PH-ILD. As detailed above, mean age in this group was 
54.9 years. 51 (67%) were female. 34 (44.7%) were classified as diffuse cutaneous systemic 
sclerosis subset. The mean pulmonary haemodynamics on right heart catheterisation were: 
mPAP 37.3 mmHg, PVR 554.6 dynes.s.cm
-5
. The median survival in this group was 34.3 
months (95% CI 23.4-55.7). 
The following variables did not predict survival on univariable analysis: age (p=0.09), gender 
(p=0.59), right atrial pressure (0.47). heart rate (0.36), cardiac output (0.29), cardiac index 
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(0.76), mean pulmonary artery pressure (p=1.00), pulmonary vascular resistance (p=0.08), 
oxygen saturation (p=0.41), mixed venous saturation (p=0.23), systolic blood pressure (p=0.37), 
diastolic blood pressure (p=0.10), six minute walking distance (p=0.10, n=47), NTproBNP 
(p=0.98, n=27), FVC % predicted (p=0.72), anti-centromere antibody status (p=0.31), anti-
topoisomerase-1 antibody status (p=0.12). 
Significant variables on univariate analysis were functional class (p=0.007), Dlco % predicted 
(p=0.03), FVC/DLCO (p=0.006) and Kco % predicted (p<0.0005, n=76). On multiple variable 
Cox analysis with these four variables, Kco % predicted is the only significant indicator 
(p=0.017). 
Kco % predicted has tertiles at 54.2 and 69.6. Kco % predicted was grouped into tertiles: <55%, 
55-70%, >70%. The hazard ratio associated with dropping by one category is 2.4 (95% CI 1.5-
3.7). 
 
 
The survival differs in three groups (p=0.0002 by log-rank). 1, 3 and 5 year survival by group is 
given below: 
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 1 yr survival 3 yr survival 5 yr survival 
Kco > 70% predicted 90.3% (67-98) 78.9% (53-92) 71.0% (43-87) 
Kco 55-70% predicted 84.4% (63-94) 53.4% (32-71) 36.0% (16-57) 
Kco < 55% predicted 80.4% (59-91) 18.5% (6-37) 9.2% (2-25) 
Discussion 
We have shown that SSc patients with PH-ILD have different demographics to patients with 
SSc-PAH: They are younger and more frequently male. In addition, they more commonly have 
diffuse scleroderma with anti-scleroderma 70 antibodies. The DLco is lower and the Kco is 
higher in the PH-ILD patients. Haemodynamic measurements at RHC are similar in the two 
groups, but patients with PH-ILD tend to have worse functional class. 
The variables most closely associated with mortality in patients with SSc, ILD and PH is a low 
Kco % predicted. We found that Kco % predicted is more closely associated with survival than 
DLco % predicted or FVC % predicted / DLco % predicted. Kco % predicted is calculated on a 
single maneouver in which a gas mixture containing small amounts of carbon monoxide and 
helium is inhaled. The concentration of these two gases in the exhaled air allows estimation of 
diffusion of carbon monoxide and alveolar volume respectively. This may be more accurate 
than separate measurements of FVC % predicted and DLco % predicted for two reasons: Firstly, 
because the tests are done simultaneously and secondly because there is no forced maneuver and 
the Kco % predicted test is therefore less effort dependent. We found that despite lower DLco % 
predicted in the PH-ILD patients the Kco % predicted is higher on average. This has not been 
observed previously to our knowledge. It may be because the efficiency of the lung in interstitial 
lung disease is not directly proportional to the change in alveolar volume. A lower Kco % 
predicted reflects dysfunction in gas diffusion which is disproportional to the volume reduction, 
which may be a measure of pulmonary vascular insufficiency. 
A recently published analysis by French investigators of 97 patients with SSc and PH, 47 of 
whom had ILD, found similar demographic differences between the two groups. They found a 
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trend towards worse survival in patients with PH-ILD over the first three years (3-year survival 
of 47% vs 71%, respectively, p=0.07). The poor prognostic factors in their analysis were 
pericardial effusion and lower DLco.  Kco was not included in their analysis.
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American investigators described a cohort of 59 patients, of whom 20 had SSc-ILD-PH. They 
found worse survival in the SSc-PH-ILD group than the SSc-PAH group with 3-year survival 
rates of 39% and 64% respectively (p<0.01 by log-rank). Poor prognostic factors (for mortality 
or transplant) in the 20 patients with ILD-PH were DLco % predicted and PVR. Kco % 
predicted was not included in their analysis.
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Our finding of 3 year survival rates of 64% in SSc-PAH and 48% in SSc-PH-ILD are very 
similar to the French and American reports. Intriguingly, although we found a significant 
difference in survival over the first three years (p=0.03 by log-rank) there was convergence later 
on, so that survival over 5 years is no longer significantly different (p=0.10), although the 
numbers of patients are smaller so this is difficult to interpret.  
It is not known whether PAH specific therapies are effective in patients with ILD-PH. In a 
French series from two centres of 70 patients with SSc and ILD-PH who were treated with PAH 
specific therapies survival was dismal with only 21% surviving 3 years.
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Our study has several limitations. We classified patients on the basis of PFTs rather than 
computed tomography scanning. Although we were constrained by availability of CT data. 
PFTs have strengths in that they are widely available, safe and are routinely performed in 
patients with SSc. In addition, studies based on CT require scoring which is not widely available 
outside academic studies. In addition, the threshold of FVC 70% was suggested by an analysis 
which combined CT scans with PFTs in a SSc cohort.
62
 We did not have six minute walking 
data and NTproBNP on most patients and could not robustly analyse these variables. We did not 
include treatment in the analysis, although most patients with SScPH-ILD are not treated with 
PH specific therapies. 
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We have shown that patients with SScPH-ILD have worse survival in the first three years 
compared to PAH, despite similar haemodynamics at RHC. Important prognostic factors are 
functional class and Kco % predicted. Mean pulmonary artery pressures and pulmonary 
vascular resistance are not associated with survival and should not form the basis for 
management decisions. Further studies are needed to clarify which treatments are effective in 
this context. 
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Chapter 8. A model to predict 
survival in patients with systemic 
sclerosis associated pulmonary 
hypertension 
Schreiber BE, Keir G, Valerio C, Handler C, Wells AU, Denton CP, Coghlan AU. Systemic 
Sclerosis associated Pulmonary Arterial Hypertension. A score to predict mortality. Oral 
presentation. Abstract 19327, American Thoracic Society, Denver, May 2011 
Objective 
The leading causes of mortality in systemic sclerosis (SSc) are interstitial lung disease (ILD) 
and pulmonary hypertension (PH).
63
 ILD occurs in about 30% of patients and PH in 10-15% of 
patients.Error! Bookmark not defined. It is known that interstitial lung disease and worsening 
pulmonary vascular resistance are associated with poor outcome in SSc-PH.
59
 We sought to 
develop a prognostic score for patients with SSc-PH to combine haemodynamic and lung 
function data. 
Patients and Methods  
Patients 
Consecutive patients (n=838) with SSc were referred to the Royal Free Pulmonary 
Hypertension service (London, UK) and had their first RHC between September 1996 and May 
2010. Investigations were performed as part of routine clinical care. Of these patients 417 were 
found to have pulmonary arterial hypertension at right heart catheter (defined as mean 
pulmonary artery pressure (mPAP) ≥ 25 mmHg and pulmonary capillary wedge pressure 
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(PCWP) < 15 mmHg). Of these patients, DLCO% predicted was unavailable in 186, FVC % 
predicted was unavailable in 179 and SpO2 was unavailable in 21. In all, 202 patients were 
excluded because of incomplete pulmonary function test data. We studied the 215 patients with 
SSc-PAH who had SpO2, FVC % predicted and DLCO % predicted within six months of the 
RHC. 
Clinical Data 
Pulse oximetry measurements were taken at the time of the RHC. Data on autoantibodies, 
weight and height were also collected. Patients with SSc overlap syndromes were included. 
Patients were classified as limited cutaneous or diffuse cutaneous subtype according to the 
criteria described by LeRoy et al.Error! Bookmark not defined. Our criteria for cardiac 
catheterization have been previously reported.
26
  
Data Analysis 
Analyses were performed using STATA
®
 software (STATA version 10.0 for Windows, Texas, 
USA). Data were expressed
 
as means (SD) or medians (range), depending on distribution.
 
Group 
comparisons were made using Student's t test. Survival analyses were compared using Log-
Rank. 
 
A P value of less than 0.05 was considered significant.  
Results 
Patient Characteristics 
We compared the patients in the study sample to those excluded [Table 1]. Our 215 patients 
were followed for an average of 24.5 months (range 0-147), a total of 616 patient-years. 
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Table 1 Descriptive statistics for patients 
Characteristic Mean (SD) or % 
study sample 
n=215 
Mean (SD) or % 
excluded  
n=202 
P value 
Age (years) 59.0 (11.3) 60.5 (12.4) 0.18 
Males 23.7 % 13.4 %  0.01 
mPAP (mmHg) 38.1 (11.0) 40.1 (12.8) 0.08 
SpO2% 94.1 (4.0) % 93.6 (4.7) 
(n=181) 
0.20 
 
Further baseline characteristics of the study cohort are given in table 2. 
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Table 2 Study participant characteristics  
Variable Mean values 
(range) 
FVC % pred 81.3 (27.4-139.6) 
DLCO % pred 37.2 (6.8-82.1) 
SpO2% pred 94.1 (71-100) 
Clinically LcSSc 76.6% 
(n=209) 
Clinically DcSSc 23.4% 
(n=209) 
ANA 95.2% 
(n=189) 
Anti-centromere +ve 42.5% 
(n=179) 
Anti-Scl70 +ve 16.4% 
(n=171) 
Overall Survival of Patients 
The overall survival of the cohort is shown below. 1 year survival is 87.6% (95% CI 82,92), 2 
year 68.8% (95% CI 61,75), 3 year 58.6% (95% CI 51,66), 5 year 39.2% (95% CI 31,48) and 10 
year 16.9% (95% CI 9,27). 
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Autoantibody does not correlate with survival 
Comparing survival in those with and without anti-centromere antibody shows no difference in 
survival (p=0.87), as does comparing patients with and without anti-Scl70 antibody (p=0.34).  
Kaplan-meier survival curves in patients grouped by antibody status 
  
Oxygen Saturation does not correlate with survival 
The median oxygen saturation was 95%, with 92% and 97% at the 25% and 75% quartiles 
respectively. Grouping patients into those above (SpO2≥95%) and below the mean 
(SpO2<95%) also does not show separation of the survival curves (p=0.20). Cox proportional 
hazards regression analysis showed that oxygen saturation does not predict survival (p=0.798). 
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FVC % predicted shows borderline association with survival 
Cox regression shows that FVC % predicted as a continuous variable does not correlate with 
survival (p=0.40). The mean FVC is 81% and median is 82%. Defining low FVC as FVC pred < 
80% gives a hazard ratio of 1.47 with borderline significance (p=0.052). Kaplan-Meier graph 
shows separation of survival curves, and log-rank analysis shows borderline significance 
(0.0503). Reducing the FVC threshold to 70% causes all association to be lost (p value by Cox 
0.43, log-rank 0.43). 
  
DLCO% predicted is associated with Survival 
Median DLCO is 35.2% predicted. Cox proportional hazards shows a strong association between 
DLCO % predicted as a continuous variable and survival (p<0.0005). Separating DLCO at the 
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median value gives a good separation of survival curves (log rank p<0.00005). Cox analysis 
shows that those with lower than median DLCO % predicted have a higher mortality than those 
above (Hazard ratio 2.27, p<0.0005). 
Age Predicts Survival 
Cox regression against age shows a significant relationship with survival (p=0.003). We formed 
a categorical value by splitting our sample into three groups by age: <50 (n=43), 50-70 (n=148) 
and >70 (n=38). The hazard ratio for age category is 1.6 (95% CI 1.1,2.2) with p=0.008. 
 
Multivariable Cox Proportional Hazards Analysis 
Multivariable Cox proportional hazards analysis was performed combining DLCO % predicted 
with mean right atrial pressure (mRAP), mean pulmonary artery pressure (mPAP), pulmonary 
vascular resistance (PVR) and cardiac output (CO). mPAP and RAP fell out during this analysis 
(p=0.119 and p=0.126 respectively). Repeating the analysis with DLCO % predicted, PVR and 
CO shows that CO also falls out (p=0.122). Thus, the best model is PVR and DLCO % predicted 
(each with p<0.0005). 
We explored use of DLCO % predicted and PVR as categorical variables. We used the median 
values as cut offs (DLCO median =35.2 %, PVR median = 453). This gave a hazard ratio of 2.00 
for low DLCO (p=0.001) and a hazard ratio of 1.58 for high PVR (p=0.03). There is no 
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significant interaction between DLCO category and PVR category (Adding in a third variable 
representing DLCO x PVR was not significant p=0.07). 
Adding in age category (0 if<50, 1 if between 50-70 and 2 if >70) remained highly significant. 
So in the final model: 
 Values Hazard Ratio 
(95% CI) 
P Value 
DLCO % category 0 if >40% 
1 if 30-40% 
2 if <30% 
1.78 (1.4-2.3) <0.0005 
PVR category 0 if <350 
1 if 350-650 
2 if >650 
1.56 (1.2-2.0) 0.001 
Age category 0 if <50 
1 if 50-70 
2 if >70 
1.58 (1.1-2.2) 0.01 
A New Prognostic Score for Patients with SSc-PAH 
We created categorical variables for DLCO and PVR by dividing each into three categories of 
equal sizes. We then rounded this to convenient numbers (DLCO cut-offs of 30.4,39.7 were 
rounded to 30,40 and PVR cut offs at 344, 635 were rounded to 350 and 650).  We then created 
a risk score by adding the PVR score (starting from the lowest third), the DLCO score (starting 
from the highest third) and the Age score. 
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DLCO % predicted >40 30-40 <30 
Score 0 1 2 
PVR ≤350 350-650 > 650 
Score 0 1 2 
Age <50 50-70 >70 
Score 0 1 2 
Risk score = DLCO score + PVR score + Age score. 
Survival by Score 
This allows us to form three large prognostic groups. Group 1 have risk score of 0-1, group 2 
have a risk score of 2-3, and group 3 have a risk score of 4-6. 
The three groups have different survival curves. At 1 year p=0.15 for diff between Group 1 and 
Group 2, p=0.03 for diff between group 2 and group 3. By 3 years they are clearly distinct 
(p=0.006 for comparison of Group 1 to Group 2 and p=0.002 for comparison of Group 2 to 
Group 3). At 5 years (p=0.0005 for comparison of Group 1 to Group 2 and p=0.0001 for 
comparison of Group 2 to Group 3).  
Each step increase in group is associated with a hazard ratio of 2.5 (95% CI 1.7,3.5) on Cox 
regression analysis (p<0.0005). 
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Group Score No. of 
patients 
1 year 
survival 
3 year 
survival 
5 year 
survival 
10 year 
survival 
Median 
survival 
(months) 
I 0-1 44 97.6% 
(84,100) 
87% 
(69,95) 
81% 
(58,92) 
46% 
(19,70) 
101.3 
(75.6,n/a) 
II 2-3 93 90% 
(81,95) 
59% 
(47,70) 
43% 
(30,55) 
13% 
(3,30) 
45.1 
(34,72) 
III 4-6 78 77% 
(65,85) 
40% 
(27,52) 
9% 
(3,21) 
- 25.2 
(19,41) 
Overall Mean 
1.97 
215 88% 
(82,92) 
59% 
(51,66) 
39% 
(31,48) 
17% 
(9,27) 
45.1 
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Conclusion 
In patients with SSc associated PH, a simple equation incorporating age, gas transfer and 
pulmonary vascular resistance provides valuable prognostic information, and may help inform 
decision-making as to when, and for whom, to commence advanced PH therapies. 
Survival scores in pulmonary arterial hypertension have been derived particularly from the 
French and American registries. The American Reveal registry score was initially derived in a 
large cohort of 2716 patients in the USA.
64
 It came to some counterintuitive results, such as 
setting the threshold for risk from high pulmonary vascular resistance at an incredibly elevated 
level of 32 wood units, which is very rarely seen. They identified several features associated 
with poor prognosis, including portal hypertension, connective tissue disease, older males, renal 
insufficiency, and pericardial effusion on echocardiography. In addition, six minute walking 
distance, brain natriuretic peptide and diffusion of carbon monoxide correlated with survival. 
They have validated the risk score in newly diagnosed as well as established patients.
65
 The risk 
score is not, however, scleroderma specific. The strength of our analysis is that it is derived in a 
scleroderma cohort and gives wide separation of groups. Independent validation would be 
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required, and further work should compare our score with the performance characteristics of the 
Reveal score in a scleroderma cohort. 
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Further Study 
Work in this thesis is being taken forward in different directions. We have undertaken further 
analyses of our data, especially studying specific subgroups such as those with dermatomyositis, 
mixed connective tissue disease and myocardial involvement. Other planned analyses include 
comparing treatments with different classes of agents and the effect of drug therapy in a 
subgroup with interstitial lung disease. 
The relationship between CT findings and pulmonary venoocclusive disease is being researched 
in a cohort of 200 scans, scored by two radiologists for features of PVOD and correlated with 
clinical findings. 
We have set up a prospective 20 year research project for the study shortness of breath in 
patients with connective tissue disease with the Royal Brompton Hospital. This has full ethics 
approval. It will allow us to collect comprehensive data sets on patients prospectively in a real 
life setting over a prolonged time course. 
We are planning a study of arrhythmias in systemic sclerosis and pulmonary hypertension using 
implanted loop recorders to detect arrhythmias prospectively in a cohort of patients with severe 
disease. 
Finally, we have a growing program of basic research studying animal models of pulmonary 
hypertension and serum taken at the time of right heart catheterisation of patients with 
pulmonary hypertension.  
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Closing Remarks 
Performing this research has undoubtedly taught me a huge amount. I feel it has given me a 
good grounding in medical statistics including in particular regression and survival analyses, as 
well as facing the limitations of retrospective data, missing data and the vicissitudes of daily life 
in clinical research. I have been clinically involved with patients with connective tissue disease, 
interstitial lung disease and pulmonary hypertension, and the research has all felt directly 
relevant to my work as a practicing physician. 
Many of the most important questions in this area remain unanswered. We still do not 
understand why patients with scleroderma develop interstitial lung disease and pulmonary 
hypertension. One of the important clinical imperatives is to make an early diagnosis in the hope 
that we can impact on progression of these complications. Chapters 1-4 addressed issues 
relating to diagnosis. While physicians have long used clinical judgement to assess whether a 
particular patient is likely to have pulmonary hypertension, statistical analysis can refine clinical 
thinking by defining the risk associated with particular clinical features and by identifying 
subtle trends which can only be appreciated when a large number of patients is analysed at once. 
Thus for example, the fact that relatively small changes in oxygen saturation greatly enhance the 
significance of a reduced diffusion of carbon monoxide may well be helpful clinically. Efforts 
are underway currently to produce a guideline driven approach to diagnosis of pulmonary 
hypertension. It is important that statistical analyses should not trump clinical thinking but 
rather enhance it. 
Some of the peculiarities of connective tissue disease associated pulmonary hypertension were 
explored next. In Chapter 5 we showed that patients with SLE tend to be younger than SSc 
patients, tend to have more responsive disease and better survival. Whether immunosuppression 
has a greater role in lupus patients is intriguing and is not yet satisfactorily addressed. 
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In chapter 6 we entered the discussion on pulmonary veno-occlusive disease and scleroderma. 
We reviewed the literature suggesting that there was a strong association between this rare 
variant of pulmonary hypertension and scleroderma and we analysed the radiological signs in a 
series of CT scans. We found that interlobular septal thickening were more common as patients 
age and that centrilobular nodules were associated with more severe pulmonary hypertension. 
Neither sign seemed to particularly correlate with pulmonary veno-occlusive disease, although 
they clearly can do so in some patients. 
The final couple of chapters were devoted to prognosis in patients with systemic sclerosis. We 
first looked at the small group of patients with interstitial lung disease and pulmonary 
hypertension who were treated with immunosuppresants as well as pulmonary vasodilators. We 
found that KCO was closely associated with survival in these patients. It seemed in a single 
measure to best encapsulate the extent of both interstitial lung disease and pulmonary 
vasculopathy. 
We then turned to survival in patients with systemic sclerosis and pulmonary hypertension and 
showed that DLCO % predicted is independently associated with survival, as is the patient’s 
age. 
In order to further the work represented in this thesis, we have set up a 20 year prospective 
study of breathlessness in connective tissue disease to capture prospectively the clinical stories 
of patients as they are investigated and treated for interstitial lung disease and pulmonary 
hypertension in particular.  
Thank you for reading the thesis. I hope it has been of some interest. 
 
Benji Schreiber 
London, April 2013 
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